Gene editing protein, corresponding gene editing system thereof, and use thereof

By developing a new CRISPR/Cas system, combining gene editing proteins with specific amino acid sequences and functional domains, the shortcomings of existing systems in targeted nucleic acid or polynucleotide editing are solved, and efficient gene editing and cleavage are achieved. Excellent application prospects and activities.

WO2024240053A1PCT designated stage expired Publication Date: 2024-11-28YOLTECH THERAPEUTICS CO LTD
View PDF 6 Cites 0 Cited by

Patent Information

Application Number
PCT/CN2024/093739
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-05-24
Filing Date
2024-05-16
Publication Date
2024-11-28

AI Technical Summary

Technical Problem

The existing CRISPR/Cas system has insufficient diversified characteristics in gene editing, making it difficult to achieve robust editing of targeted nucleic acids or polynucleotides, and has certain advantages and disadvantages, which cannot meet the wide application needs of biotechnology development.

Method used

A new CRISPR/Cas system has been developed, including gene editing proteins and fusion proteins with specific amino acid sequences, and through combination with functional domains, it provides a diverse gene editing tool that can effectively edit or cleave target genes.

Benefits of technology

It has achieved efficient editing or cleavage of target genes, has broad application prospects, can effectively treat a variety of diseases, demonstrates excellent DNA nuclease activity, and surpasses the Cas enzyme performance in the prior art.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure PCTCN2024093739-FTAPPB-I100001
    Figure PCTCN2024093739-FTAPPB-I100001
  • Figure PCTCN2024093739-FTAPPB-I100002
    Figure PCTCN2024093739-FTAPPB-I100002
  • Figure PCTCN2024093739-FTAPPB-I100003
    Figure PCTCN2024093739-FTAPPB-I100003
Patent Text Reader

Abstract

Provided are a gene editing protein, a corresponding gene editing system thereof, and a use thereof. Specifically, the gene editing protein shows gene editing activity in vitro, can effectively edit or cut a target gene, and can effectively treat disorders or diseases of a subject in need.
Need to check novelty before this filing date? Find Prior Art

Description

A gene editing protein, its corresponding gene editing system and application Technical Field

[0001] The present invention relates to the field of gene editing, and in particular, to a gene editing protein, a corresponding gene editing system and applications. Background Art

[0002] Clustered regularly interspaced short palindromic repeats (CRISPR) systems are a DNA defense mechanism developed by bacteria and archaea to prevent invading phages. CRISPR systems comprise two families: type 1 systems are further divided into types I, III, and IV; and type 2 systems are further divided into types II, V, and VI. These six system types are further subdivided into 19 subtypes. Many prokaryotes harbor multiple CRISPR-Cas systems, suggesting that they are compatible and may share components.

[0003] The most common type II system is the CRISPR / Cas9 system. The Cas9 protein, with the assistance of a trans-encoded small RNA (tracrRNA), processes pre-crRNA into mature crRNA that binds to tracrRNA. Subsequently, it was discovered that artificially constructing a single-stranded chimeric guide RNA (gRNA) that mimics the crRNA-tracrRNA complex can effectively mediate target recognition and cleavage by the Cas9 protein. The three bases immediately adjacent to the 3′ end of the target must be in the form of 5′-NGG-3′, thus forming the PAM (protospacer adjacent motif) structure required for target recognition by the Cas / crRNA complex.

[0004] Currently known CRISPR / Cas have their own advantages and disadvantages. For example, Cas9 requires two RNAs as guide RNAs.

[0005] There is an urgent need for alternative and robust editing systems and technologies targeting nucleic acids or polynucleotides with broad application value.

[0006] Therefore, the current development of biotechnology still requires the development of new CRISPR / Cas systems with diverse characteristics.

[0007] Summary of the Invention

[0008] The main purpose of the present invention is to provide a new CRISPR / Cas system with diverse characteristics.

[0009] Another object of the present invention is to discover new CRISPR-Cas systems to provide alternative and robust systems and techniques for targeting nucleic acids or polynucleotides to address the shortcomings of currently known CRISPR-Cas systems.

[0010] The first aspect of the present invention provides a gene editing protein, wherein the protein is selected from the group consisting of:

[0011] (a) a polypeptide having the amino acid sequence shown in SEQ ID NO: 1;

[0012] (b) a polypeptide having ≥80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 99.5% homology (or identity) to the amino acid sequence of SEQ ID NO: 1, and the polypeptide has the biological function of SEQ ID NO: 1;

[0013] (c) a derivative polypeptide formed by substituting, deleting or adding one or more (preferably 1-20, more preferably 1-10, and even more preferably 1-5) amino acid residues of any one of the amino acid sequences shown in SEQ ID NO: 1, and retaining the biological function of SEQ ID NO: 1.

[0014] In another preferred embodiment, the gene editing protein is an effector protein in the CRISPR / Cas system.

[0015] The second aspect of the present invention provides a fusion protein comprising the gene editing protein described in the first aspect of the present invention; and one or more functional domains.

[0016] In another preferred embodiment, the functional domain is selected from a localization signal, a reporter protein, a Cas protein targeting portion, a DNA binding domain, an epitope tag, a transcription activation domain, a transcription repression domain, a nuclease, a deamination domain, a methylase, a demethylase, a transcription release factor, an HDAC, a cleavage active polypeptide, a ligase, an integrase, a transposase, a recombinase, a polymerase, and a base excision repair inhibitor (such as a uracil-DNA glycosylase inhibitor (UGI)).

[0017] In another preferred example, the functional domain includes one or more of the following enzymatic activities on the target sequence: methylase activity, demethylase activity, acetyltransferase activity, deacetylase activity, kinase activity, phosphatase activity, ubiquitin ligase activity, deubiquitination activity, adenylation activity, deadenylation activity, SUMOylation activity, deSUMOylation activity, ribosylation activity, deribosylation activity, myristoylation activity, demyristoylation activity, glycosylation activity (e.g., from O-GlcNAc transferase) and deglycosylation activity.

[0018] In another preferred embodiment, the functional domain is selected from the adenosine deaminase catalytic domain or the cytidine deaminase catalytic domain.

[0019] In another preferred embodiment, the adenosine deaminase catalytic domain or the cytidine deaminase catalytic domain includes one or more of ADAR1, ADAR2, APOBEC, AID or TAD.

[0020] In another preferred embodiment, the functional domain is the full length or functional fragment of TadA8e.

[0021] In another preferred embodiment, the localization signal includes a nuclear localization signal (NLS) and / or a nuclear export signal (NES).

[0022] In another preferred embodiment, the sequence of the nuclear localization signal is located at, near or close to the end (eg, N-terminus or C-terminus) of the protein according to claim 1.

[0023] In another preferred embodiment, the nuclear export signal includes protein tyrosine kinase 2 (such as human protein tyrosine kinase 2).

[0024] In another preferred embodiment, the reporter protein includes glutathione-S-transferase (GST), horseradish peroxidase (HRP), chloramphenicol acetyltransferase (CAT), β-galactosidase, β-glucuronidase, and autofluorescent protein.

[0025] In another preferred embodiment, the autofluorescent protein includes green fluorescent protein (e.g., GFP, GFP-2, tagGFP, turboGFP, eGFP, CopGFP, AceGFP, etc.), HcRed, DsRed, cyan fluorescent protein (e.g., eCFP, Cerulean, CyPet, AmCyanl, etc.), yellow fluorescent protein (e.g., YFP, eYFP, Citrine, Venus, YPet, PhiYFP, etc.), blue fluorescent protein (e.g., eBFP, eBFP2, Azurite, mKalamal, GFPuv, Sapphire, T-sapphire).

[0026] In another preferred embodiment, the DNA binding domain includes methylation binding protein, LexADBD, and Gal4DBD.

[0027] In another preferred embodiment, the epitope tag includes a histidine tag, a V5 tag, a FLAG tag, an influenza virus hemagglutinin tag, a Myc tag, a VSV-G tag, a thioredoxin tag, or a streptavidin tag.

[0028] In another preferred embodiment, the transcriptional activation domain includes VP64 and / or VPR.

[0029] In another preferred embodiment, the transcriptional repression domain includes KRAB and / or SID.

[0030] In another preferred embodiment, the nuclease includes FokI.

[0031] In another preferred embodiment, the cleavage active polypeptide includes a polypeptide having single-stranded RNA cleavage activity, a polypeptide having double-stranded RNA cleavage activity, a polypeptide having single-stranded DNA cleavage activity or a polypeptide having double-stranded DNA cleavage activity.

[0032] In another preferred embodiment, the ligase includes DNA ligase and / or RNA ligase.

[0033] In another preferred embodiment, the functional domain is connected to the N-terminus and / or C-terminus of the gene editing protein.

[0034] In another preferred embodiment, the functional domain is inserted between the N-terminus and the C-terminus of the gene editing protein.

[0035] In another preferred embodiment, the one or more functional domains are optionally connected to the N-terminus and / or C-terminus of the gene editing protein via a linker.

[0036] In another preferred embodiment, the functional domain is inserted between the N-terminus and C-terminus of the gene editing protein through a linker.

[0037] In another preferred embodiment, the fusion protein has the following structure from N-terminus to C-terminus:

[0038] Z1-Z2(I); or

[0039] Z2-Z1(II); or

[0040] Z3-Z1-Z4(III);

[0041] wherein Z1 is cytosine deaminase or adenosine deaminase;

[0042] Z2 is the gene editing protein described in the first aspect of the present invention;

[0043] Z3 is the N-terminal fragment of the gene editing protein described in the first aspect of the present invention;

[0044] Z4 is the C-terminal fragment of the gene editing protein described in the first aspect of the present invention;

[0045] Furthermore, each "-" is independently a bond or a linker.

[0046] The third aspect of the present invention provides an isolated polynucleotide, which encodes the gene editing protein described in the first aspect of the present invention or the fusion protein described in the second aspect of the present invention.

[0047] In another preferred embodiment, the polynucleotide is selected from the following group:

[0048] (a) a polynucleotide whose sequence is shown in SEQ ID NO. 2;

[0049] (b) a polynucleotide having a nucleotide sequence identity of ≥70% (preferably ≥80%, more preferably ≥90%, more preferably ≥95%, and most preferably ≥99%) to the sequence shown in SEQ ID NO. 2 and encoding the polypeptide shown in SEQ ID NO. 1;

[0050] (c) A polynucleotide complementary to the polynucleotide described in any one of (a) to (b).

[0051] In another preferred embodiment, the polynucleotide further contains auxiliary elements flanking the ORF of the variant selected from the following group: a signal peptide, a secretory peptide, a tag sequence (such as 6His), or a combination thereof.

[0052] In another preferred embodiment, the polynucleotide is selected from the following group: genomic sequence, cDNA sequence, RNA sequence, or a combination thereof.

[0053] In another preferred embodiment, the polynucleotide further comprises a promoter operably linked to the ORF sequence of the variant.

[0054] In another preferred embodiment, the promoter is selected from the following group: a constitutive promoter, a tissue-specific promoter, an inducible promoter, or a strong promoter.

[0055] In another preferred embodiment, the host cell includes a prokaryotic cell or a eukaryotic cell.

[0056] In another preferred embodiment, the host cell is a eukaryotic cell, such as a yeast cell, a plant cell or a mammalian cell (including human and non-human mammals).

[0057] In another preferred embodiment, the host cell is a prokaryotic cell, such as Escherichia coli.

[0058] In another preferred embodiment, the yeast cell is selected from one or more yeasts of the following sources: Pichia pastoris, Kluyveromyces, or a combination thereof; preferably, the yeast cell includes: Kluyveromyces, more preferably Kluyveromyces marxianus, and / or Kluyveromyces lactis.

[0059] In another preferred embodiment, the host cell is selected from the group consisting of Escherichia coli, wheat germ cells, insect cells, SF9, Hela, HEK293, CHO, yeast cells, or a combination thereof.

[0060] A fourth aspect of the present invention provides an isolated nucleic acid molecule comprising or consisting of a sequence selected from the following:

[0061] (i) the sequence shown in SEQ ID NO: 3;

[0062] (ii) a sequence having one or more base substitutions, deletions or additions (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 base substitutions, deletions or additions) compared to the sequence shown in SEQ ID NO: 3;

[0063] (iii) a sequence having at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, or at least 95% sequence identity to the sequence set forth in SEQ ID NO: 3;

[0064] (iv) a sequence that hybridizes under stringent conditions to the sequence described in any one of (i) to (iii); or

[0065] (v) a complementary sequence of the sequence described in any one of (i) to (iii);

[0066] Furthermore, the sequence of any one of (ii) to (v) substantially retains the biological function of the sequence from which it is derived;

[0067] For example, the isolated nucleic acid molecule is RNA;

[0068] For example, the isolated nucleic acid molecule comprises a direct repeat sequence in a CRISPR / Cas system.

[0069] In another preferred embodiment, the nucleic acid molecule comprises one or more stem-loops or optimized secondary structures;

[0070] For example, the sequence of any of (ii)-(v) retains the secondary structure of the sequence from which it is derived.

[0071] In another preferred embodiment, the nucleic acid molecule comprises a sequence selected from the following, or consists of a sequence selected from the following:

[0072] (a) the nucleotide sequence shown in SEQ ID NO: 3;

[0073] (b) a sequence that hybridizes under stringent conditions to the sequence described in (a); or

[0074] (c) The complementary sequence of the nucleotide sequence shown in SEQ ID NO: 3.

[0075] The fifth aspect of the present invention provides a guide RNA (gRNA), which includes a direct repeat (DR) sequence capable of binding to the gene editing protein described in the first aspect of the present invention and a spacer sequence capable of targeting the target sequence.

[0076] A sixth aspect of the present invention provides a composite comprising:

[0077] (i) a protein component selected from the group consisting of the gene editing protein described in the first aspect of the present invention, the fusion protein described in the second aspect of the present invention, or a combination thereof; and

[0078] (ii) a nucleic acid component selected from the group consisting of the guide RNA of the fifth aspect of the present invention, a nucleic acid encoding the guide RNA of the fifth aspect of the present invention, a precursor RNA of the guide RNA of the fifth aspect of the present invention, a precursor RNA nucleic acid encoding the guide RNA of the fifth aspect of the present invention, or a combination thereof;

[0079] Wherein, the protein component and the nucleic acid component combine with each other to form a complex.

[0080] In another preferred embodiment, the direct repeat (DR) sequence in the guide RNA (gRNA) is connected to the 3' end or the 5' end of the nucleic acid molecule.

[0081] In another preferred embodiment, the spacer sequence in the guide RNA (gRNA) comprises a complementary sequence to the target sequence.

[0082] The seventh aspect of the present invention provides a vector comprising the polynucleotide described in the third aspect of the present invention or the nucleic acid molecule described in the fourth aspect of the present invention.

[0083] In another preferred embodiment, the vector comprises:

[0084] (1) a first regulatory element, which is operably linked to a nucleotide sequence encoding the gene editing protein of the first aspect of the present invention or a nucleotide sequence encoding the fusion protein of the second aspect of the present invention; and

[0085] (2) a second regulatory element, the second regulatory element being operably linked to a nucleotide sequence encoding a guide RNA, the guide RNA comprising:

[0086] (a) a spacer sequence capable of hybridizing to the target sequence, and

[0087] (b) a direct repeat (DR) sequence, which is connected to the spacer sequence and can guide the gene editing protein described in the first aspect of the present invention to bind to the guide RNA to form the complex described in the sixth aspect of the present invention that targets the target sequence.

[0088] In another preferred embodiment, the first regulatory element and the second regulatory element are located on the same or different vectors.

[0089] In another preferred embodiment, the first regulatory element and / or the second regulatory element is a promoter, such as an inducible promoter.

[0090] In another preferred embodiment, the vector comprises one or more promoters, which are operably connected to the nucleic acid sequence, enhancer, transcription termination signal, polyadenylation sequence, replication origin, selective marker, nucleic acid restriction site, and / or homologous recombination site.

[0091] In another preferred embodiment, the vector includes a plasmid or a viral vector.

[0092] In another preferred embodiment, the viral vector is selected from the group consisting of adeno-associated virus (AAV), adenovirus, lentivirus, retrovirus, herpes virus, SV40, poxvirus, or a combination thereof.

[0093] In another preferred embodiment, the vector includes a cloning vector, a transformation vector, an expression vector, a shuttle vector, an integration vector, and a multifunctional vector.

[0094] An eighth aspect of the present invention provides a CRISPR-Cas composition comprising:

[0095] (i) a first component selected from the group consisting of the gene editing protein of the first aspect of the invention, the fusion protein of the second aspect of the invention, a nucleotide sequence encoding the gene editing protein of the first aspect of the invention or the fusion protein of the second aspect of the invention, and any combination thereof; and

[0096] (ii) a second component, which comprises one or more guide RNAs according to the fifth aspect of the present invention, or a nucleotide sequence encoding the guide RNAs according to the fifth aspect of the present invention;

[0097] The guide RNA is capable of forming a complex with the protein, protein variant or fusion protein described in (i).

[0098] In another preferred embodiment, the guide RNA comprises a direct repeat sequence and a spacer sequence from the 5' to the 3' direction, and the spacer sequence is capable of hybridizing with the target sequence.

[0099] In another preferred embodiment, the direct repeat sequence is the nucleic acid molecule defined in the fourth aspect of the present invention.

[0100] In another preferred embodiment, the composition further comprises a pharmaceutically acceptable carrier.

[0101] In another preferred embodiment, the composition comprises a pharmaceutical composition.

[0102] In another preferred embodiment, the dosage form of the composition is selected from the following group: a lyophilized preparation, a liquid preparation, or a combination thereof.

[0103] In another preferred embodiment, the composition is in the form of a liquid preparation.

[0104] In another preferred embodiment, the composition is in the form of an injection.

[0105] In another preferred embodiment, the composition is a cell preparation.

[0106] A ninth aspect of the present invention provides a CRISPR-Cas system comprising one or more vectors, wherein the one or more vectors comprise:

[0107] (i) a first nucleic acid, which is a nucleotide sequence encoding the gene editing protein of the first aspect of the present invention or the fusion protein of the second aspect of the present invention; optionally, the first nucleic acid is operably linked to a first regulatory element; and

[0108] (ii) a second nucleic acid encoding a nucleotide sequence comprising the guide RNA according to the fifth aspect of the present invention; optionally, the second nucleic acid is operably linked to a second regulatory element;

[0109] in:

[0110] The first nucleic acid and the second nucleic acid are present on the same or different vectors;

[0111] The guide RNA is capable of forming a complex with the protein or fusion protein described in (i).

[0112] In another preferred embodiment, the vector includes a plasmid or a viral vector.

[0113] In another preferred embodiment, the guide RNA includes a spacer sequence capable of hybridizing with a target sequence; and a direct repeat (DR) sequence connected to the spacer sequence and capable of guiding the protein to bind to the guide RNA, thereby forming a CRISPR-Cas composition or complex targeting the target sequence.

[0114] In another preferred embodiment, the guide RNA includes unmodified and modified guide RNA.

[0115] In another preferred embodiment, the modified guide RNA includes chemical modification of the bases.

[0116] In another preferred embodiment, the chemical modification includes methylation modification, methoxy modification, fluorination modification or thio modification.

[0117] In another preferred embodiment, the direct repeat sequence is the nucleic acid molecule defined in claim 4.

[0118] In another preferred embodiment, the first regulatory element and / or the second regulatory element is a promoter, such as an inducible promoter.

[0119] In another preferred embodiment, at least one component in the composition is non-naturally occurring or modified.

[0120] In another preferred embodiment, the spacer sequence is connected to the 3' end of the direct repeat (DR) sequence.

[0121] In another preferred embodiment, the spacer sequence comprises a complementary sequence to the target sequence.

[0122] In another preferred embodiment, when the target sequence is DNA, the target sequence is located at the 3' end of the protospacer sequence adjacent to the motif (PAM), and the PAM has a sequence represented by 5'-PAM being TTTN, and N is A, T, C or G.

[0123] In another preferred embodiment, the target sequence is a DNA from a prokaryotic cell or a eukaryotic cell, or a DNA sequence formed based on RNA reverse transcription; or, the target sequence is a non-naturally occurring DNA, or a DNA sequence formed based on RNA reverse transcription.

[0124] In another preferred embodiment, the target sequence includes a cDNA sequence.

[0125] In another preferred embodiment, the target sequence includes single-stranded DNA and double-stranded DNA sequences.

[0126] In another preferred embodiment, the target sequence exists within a cell.

[0127] In another preferred embodiment, the target sequence is present in the cell nucleus or cytoplasm (eg, an organelle).

[0128] In another preferred embodiment, the cell is a eukaryotic cell.

[0129] In another preferred embodiment, the cell is a prokaryotic cell.

[0130] In another preferred embodiment, the target sequence exists outside the cell.

[0131] In another preferred embodiment, the gene editing protein according to the first aspect of the present invention is connected to one or more NLS sequences, or the fusion protein contains one or more NLS sequences.

[0132] In another preferred embodiment, the NLS sequence is connected to the N-terminus or C-terminus of the gene editing protein described in the first aspect of the present invention.

[0133] In another preferred embodiment, the NLS sequence is fused to the N-terminus or C-terminus of the gene editing protein described in the first aspect of the present invention.

[0134] The tenth aspect of the present invention provides a kit comprising one or more components selected from the following: the gene editing protein described in the first aspect of the present invention, the fusion protein described in the second aspect of the present invention, the polynucleotide described in the third aspect of the present invention, the complex described in the sixth aspect of the present invention, the vector described in the seventh aspect of the present invention, the CRISPR-Cas composition described in the eighth aspect of the present invention, or the system described in the ninth aspect of the present invention.

[0135] In another preferred embodiment, the kit further comprises a label or instructions.

[0136] In another preferred embodiment, the kit is used for one or more of gene or genome editing, disease treatment, target gene targeting, and cutting of target genes or non-target genes.

[0137] The eleventh aspect of the present invention provides a delivery composition comprising a delivery vector and one or more selected from the following: the gene editing protein described in the first aspect of the present invention, the fusion protein described in the second aspect of the present invention, the polynucleotide described in the third aspect of the present invention, the complex described in the sixth aspect of the present invention, the vector described in the seventh aspect of the present invention, the CRISPR-Cas composition described in the eighth aspect of the present invention, or the system described in the ninth aspect of the present invention.

[0138] In another preferred embodiment, the delivery vehicle is a particle.

[0139] In another preferred embodiment, the delivery vector is selected from lipid particles, sugar particles, metal particles, protein particles, liposomes, exosomes, microbubbles, gene guns or viral vectors (e.g., replication-defective retroviruses, lentiviruses, adenoviruses or adeno-associated viruses).

[0140] The twelfth aspect of the present invention provides a host cell comprising the gene editing protein described in the first aspect of the present invention, the fusion protein described in the second aspect of the present invention, the polynucleotide described in the third aspect of the present invention, the nucleic acid molecule described in the fourth aspect of the present invention, the complex described in the sixth aspect of the present invention, the vector described in the seventh aspect of the present invention, the CRISPR-Cas composition described in the eighth aspect of the present invention, or the system described in the ninth aspect of the present invention, or the delivery composition described in the eleventh aspect of the present invention.

[0141] In another preferred embodiment, the host cell is a eukaryotic cell, such as a yeast cell, a plant cell or a mammalian cell (including human and non-human mammals).

[0142] In another preferred embodiment, the host cell is a prokaryotic cell, such as Escherichia coli.

[0143] In another preferred embodiment, the yeast cell is selected from one or more yeasts of the following sources: Pichia pastoris, Kluyveromyces, or a combination thereof; preferably, the yeast cell includes: Kluyveromyces, more preferably Kluyveromyces marxianus, and / or Kluyveromyces lactis.

[0144] In another preferred embodiment, the host cell is selected from the group consisting of Escherichia coli, wheat germ cells, insect cells, SF9, Hela, HEK293, CHO, yeast cells, or a combination thereof.

[0145] The thirteenth aspect of the present invention provides an enzyme preparation, which includes the gene editing protein described in the first aspect of the present invention, the fusion protein described in the second aspect of the present invention, the complex described in the sixth aspect of the present invention, the CRISPR-Cas composition described in the eighth aspect of the present invention, or the system described in the ninth aspect of the present invention, or the delivery composition described in the eleventh aspect of the present invention.

[0146] In another preferred embodiment, the enzyme preparation includes an injection and / or a freeze-dried preparation.

[0147] A fourteenth aspect of the present invention provides a medicine kit comprising:

[0148] A first container, and the complex described in the sixth aspect of the present invention, the composition described in the eighth aspect of the present invention, or the system described in the ninth aspect of the present invention located in the first container, or a drug containing the complex described in the sixth aspect of the present invention, the composition described in the eighth aspect of the present invention, or the system described in the ninth aspect of the present invention.

[0149] In another preferred embodiment, the drug in the first container is a single-ingredient preparation containing the complex described in the sixth aspect of the present invention, the composition described in the eighth aspect of the present invention, or the system described in the ninth aspect of the present invention.

[0150] In another preferred embodiment, the dosage form of the drug is selected from the following group: a lyophilized preparation, a liquid preparation, or a combination thereof.

[0151] In another preferred embodiment, the dosage form of the drug is an oral dosage form or an injection dosage form.

[0152] In another preferred embodiment, the medicine kit further contains instructions.

[0153] A fifteenth aspect of the present invention provides a medicine kit comprising:

[0154] (a1) a first container, and the gene-editing protein of the first aspect of the present invention, or the fusion protein of the second aspect of the present invention, or a gene encoding the same or an expression vector thereof, or a drug containing the gene-editing protein of the first aspect of the present invention, or the fusion protein of the second aspect of the present invention, or a gene encoding the same or an expression vector thereof, located in the first container;

[0155] (b1) an optional second container, and the guide RNA or its expression vector according to the fifth aspect of the present invention, or a drug containing the guide RNA or its expression vector according to the fifth aspect of the present invention, located in the second container.

[0156] In another preferred embodiment, the first container and the second container are different containers.

[0157] In another preferred embodiment, the medicine in the first container is a single-ingredient preparation containing the gene editing protein described in the first aspect of the present invention, or the fusion protein described in the second aspect of the present invention, or its encoding gene or its expression vector.

[0158] In another preferred embodiment, the medicine in the second container is a single-ingredient preparation containing the guide RNA or its expression vector described in the fifth aspect of the present invention.

[0159] In another preferred embodiment, the dosage form of the drug is selected from the following group: a lyophilized preparation, a liquid preparation, or a combination thereof.

[0160] In another preferred embodiment, the dosage form of the drug is an oral dosage form or an injection dosage form.

[0161] In another preferred embodiment, the medicine kit further contains instructions.

[0162] The sixteenth aspect of the present invention provides a method for targeting and editing a target gene or cutting a target gene, comprising: the gene editing protein described in the first aspect of the present invention, or the fusion protein described in the second aspect of the present invention, or the complex described in the sixth aspect of the present invention, or the composition described in the eighth aspect of the present invention, or the system described in the ninth aspect of the present invention, or the delivery composition described in the eleventh aspect of the present invention, or the enzyme preparation described in the thirteenth aspect of the present invention, or the drug kit described in the fourteenth aspect of the present invention or the fifteenth aspect of the present invention is contacted with the target gene, or delivered to a cell containing the target gene, and the target sequence is present in the target gene.

[0163] In another preferred embodiment, the target gene exists in cells.

[0164] In another preferred embodiment, the cell is a prokaryotic cell.

[0165] In another preferred embodiment, the cell is a eukaryotic cell, such as a mammalian cell (such as a human cell) or a plant cell.

[0166] In another preferred embodiment, the target gene exists in a nucleic acid molecule (eg, a plasmid) in vitro.

[0167] In another preferred embodiment, the editing of the target gene or the cutting of the target gene includes breaking the target sequence, such as double-strand break of DNA or single-strand break of RNA, or inserting exogenous nucleic acid into the break.

[0168] In another preferred embodiment, the target gene comprises DNA.

[0169] In another preferred embodiment, the DNA includes single-stranded DNA and double-stranded DNA.

[0170] The seventeenth aspect of the present invention provides a method for inducing a change in a cell state, the method comprising contacting the gene editing protein described in the first aspect of the present invention, or the fusion protein described in the second aspect of the present invention, or the complex described in the sixth aspect of the present invention, or the composition described in the eighth aspect of the present invention, or the system described in the ninth aspect of the present invention, or the delivery composition described in the eleventh aspect of the present invention, or the enzyme preparation described in the thirteenth aspect of the present invention, or the drug kit described in the fourteenth aspect of the present invention or the fifteenth aspect of the present invention with a target gene in a cell.

[0171] The eighteenth aspect of the present invention provides a method for changing the expression of a gene product, comprising: contacting the gene editing protein described in the first aspect of the present invention, or the fusion protein described in the second aspect of the present invention, or the complex described in the sixth aspect of the present invention, or the composition described in the eighth aspect of the present invention, or the system described in the ninth aspect of the present invention, or the delivery composition described in the eleventh aspect of the present invention, or the enzyme preparation described in the thirteenth aspect of the present invention, or the drug kit described in the fourteenth aspect of the present invention or the fifteenth aspect of the present invention with a nucleic acid molecule encoding the gene product, or delivering it to a cell containing the nucleic acid molecule, wherein the target sequence is present in the nucleic acid molecule.

[0172] In another preferred embodiment, the nucleic acid molecule is present in an in vitro nucleic acid molecule (eg, a plasmid).

[0173] In another preferred embodiment, the expression of the gene product is altered (eg, enhanced or decreased).

[0174] In another preferred embodiment, the gene product is a protein.

[0175] In another preferred embodiment, the protein, fusion protein, polynucleotide, isolated nucleic acid molecule, complex, vector or composition is contained in a delivery vehicle.

[0176] In another preferred embodiment, the delivery vector is selected from lipid particles, sugar particles, metal particles, protein particles, liposomes, exosomes, viral vectors (such as replication-defective retroviruses, lentiviruses, adenoviruses or adeno-associated viruses).

[0177] In another preferred embodiment, the method is used to modify a cell, cell line or organism by changing one or more target sequences in a target gene or a nucleic acid molecule encoding a target gene product.

[0178] The nineteenth aspect of the present invention provides a cell or progeny thereof obtained by the method of any one of the sixteenth to eighteenth aspects of the present invention, wherein the cell comprises a modification that is not present in its wild type.

[0179] The twentieth aspect of the present invention provides a cell product of the cell or its progeny according to the nineteenth aspect of the present invention.

[0180] The twenty-first aspect of the present invention provides an in vitro, ex vivo or in vivo cell or cell line or their progeny, wherein the cell or cell line or their progeny comprises: the gene editing protein described in the first aspect of the present invention, or the fusion protein described in the second aspect of the present invention, or the polynucleotide described in the third aspect of the present invention, or the complex described in the sixth aspect of the present invention, or the vector described in the seventh aspect of the present invention, or the composition described in the eighth aspect of the present invention, or the system described in the ninth aspect of the present invention, or the delivery composition described in the eleventh aspect of the present invention.

[0181] In another preferred embodiment, the cell is a prokaryotic cell.

[0182] In another preferred embodiment, the cell is a eukaryotic cell, such as a mammalian cell (such as a human cell) or a plant cell.

[0183] In another preferred embodiment, the cells are stem cells or stem cell lines.

[0184] The twenty-second aspect of the present invention provides the use of the gene editing protein described in the first aspect of the present invention, or the fusion protein described in the second aspect of the present invention, or the polynucleotide described in the third aspect of the present invention, or the complex described in the sixth aspect of the present invention, or the vector described in the seventh aspect of the present invention, or the composition described in the eighth aspect of the present invention, or the system described in the ninth aspect of the present invention, or the kit described in the tenth aspect of the present invention, or the delivery composition described in the eleventh aspect of the present invention, or the enzyme preparation described in the thirteenth aspect of the present invention, or the medicine box described in the fourteenth aspect of the present invention or the fifteenth aspect of the present invention, for preparing a drug or preparation, wherein the drug or preparation is used for nucleic acid editing (for example, gene or genome editing).

[0185] In another preferred embodiment, the gene or genome editing includes modifying genes, knocking out genes, changing the expression of gene products, repairing mutations, and / or inserting polynucleotides.

[0186] The twenty-third aspect of the present invention provides a use of the gene editing protein according to the first aspect of the present invention, or the fusion protein according to the second aspect of the present invention, or the polynucleotide according to the third aspect of the present invention, or the complex according to the sixth aspect of the present invention, or the vector according to the seventh aspect of the present invention, or the composition according to the eighth aspect of the present invention, or the system according to the ninth aspect of the present invention, or the kit according to the tenth aspect of the present invention, or the delivery composition according to the eleventh aspect of the present invention, or the enzyme preparation according to the thirteenth aspect of the present invention, or the drug kit according to the fourteenth aspect of the present invention or the fifteenth aspect of the present invention, for preparing a drug or preparation, wherein the drug or preparation is used for one or more selected from the following groups:

[0187] (i) ex vivo gene or genome editing;

[0188] (ii) detection of single-stranded DNA in vitro;

[0189] (iii) editing a target sequence in a target locus to modify an organism or non-human organism;

[0190] (iv) treating a disorder caused by a defect in the target sequence in the target locus;

[0191] (v) treating a condition or disease in a subject in need thereof.

[0192] In another preferred embodiment, the disease or illness includes cancer, infectious disease, neurological disease, ophthalmic disease, and hearing disease.

[0193] In another preferred embodiment, the disease or condition comprises cystic fibrosis, atherosclerotic cardiovascular disease (ASCVD), Duchenne muscular dystrophy (DMD), Becker muscular dystrophy, alpha-1-antitrypsin deficiency, Pompe disease (glycogen storage disease type II), myotonic dystrophy, Huntington's disease, fragile X syndrome, Friedreich's ataxia, amyotrophic lateral sclerosis, hereditary chronic kidney disease, sickle cell disease, primary hyperoxaluria (PH1), beta thalassemia, frontotemporal dementia, Leber's congenital amaurosis, hyperlipidemia, hypercholesterolemia (FH), hereditary angioedema (HAE), transthyretin amyloidosis (ATTR), hepatitis B (Hepatitis B). B), retinal diseases, macular degeneration, Wilms' tumor, Ewing sarcoma, neuroendocrine tumors, glioblastoma, neuroblastoma, melanoma, skin cancer, breast cancer, colon cancer, rectal cancer, prostate cancer, liver cancer, kidney cancer, pancreatic cancer, lung cancer, biliary tract cancer, cervical cancer, endometrial cancer, esophageal cancer, gastric cancer, head and neck cancer, medullary thyroid cancer, ovarian cancer, glioma, lymphoma, leukemia, myeloma, acute lymphoblastic leukemia, acute myeloid leukemia, chronic lymphocytic leukemia, chronic myeloid leukemia, Hodgkin's lymphoma, non-Hodgkin's lymphoma and urinary bladder cancer.

[0194] In another preferred embodiment, the disorder or disease is caused by a pathogenic point mutation.

[0195] The twenty-fourth aspect of the present invention provides a method for detecting whether a target nucleic acid molecule is present in a sample, the method comprising contacting the sample with the gene editing protein described in the first aspect of the present invention, or the fusion protein described in the second aspect of the present invention, or the complex described in the sixth aspect of the present invention, or the composition described in the eighth aspect of the present invention, or the system described in the ninth aspect of the present invention, or the kit described in the tenth aspect of the present invention, or the delivery composition described in the eleventh aspect of the present invention, or the enzyme preparation described in the thirteenth aspect of the present invention, and a non-target sequence, detecting a detectable signal generated by the cleavage of the non-target sequence, thereby detecting the target nucleic acid molecule, and the non-target sequence does not hybridize with the guide RNA.

[0196] In another preferred example, if the non-target sequence is cleaved by a protein in the complex or CRISPR-Cas composition or system or delivery composition, it indicates that the target nucleic acid molecule is present in the sample; and if the non-target sequence is not cleaved by a protein in the complex or CRISPR-Cas composition or system or delivery composition, it indicates that the target nucleic acid molecule is not present in the sample.

[0197] In another preferred embodiment, the target nucleic acid molecule is a target DNA.

[0198] In another preferred embodiment, the target DNA includes DNA formed based on RNA reverse transcription.

[0199] In another preferred embodiment, the target DNA includes cDNA.

[0200] In another preferred embodiment, the target DNA is selected from the group consisting of single-stranded DNA, double-stranded DNA, or a combination thereof.

[0201] It should be understood that within the scope of the present invention, the above-mentioned technical features of the present invention and the technical features described in detail below (such as in the embodiments) can be combined with each other to form new or preferred technical solutions. Due to space limitations, they will not be listed here one by one. BRIEF DESCRIPTION OF THE DRAWINGS

[0202] FIG1 shows an agarose gel electrophoresis diagram of the CasW1 insert fragment and the pET-28a(+) vector double-digested by EcoRI and NotI.

[0203] FIG2 shows the SDS-PAGE Coomassie Brilliant Blue staining of the newly purified CasW1 protein.

[0204] FIG3 shows an agarose gel electrophoresis diagram of dsDNA template prepared in vitro.

[0205] Figure 4 shows the capillary electrophoresis diagram for the identification of the in vitro cleavage effect of CasW1. Taking the in vitro cleavage effect of Cpf1 as a control, it can be seen that CasW1 can cleave a 450bp dsDNA template into two dsDNA fragments, and the cleavage activity is close to 100%.

[0206] Figure 5 shows a capillary electrophoresis diagram for identifying the cleavage effect of CasW1 in vitro, with Cas12i.16 and S7R-Cas12i3 (M2869) in the prior art as controls.

[0207] FIG6 shows the plasmid map of pET-28a(+)-CasW1.

[0208] FIG. 7 shows a plasmid map of pET-28a(+)-LbCpf1.

[0209] FIG8 shows the plasmid map of pET-28a(+)-HED Cas12i.16.

[0210] FIG9 shows a plasmid map of pET-28a(+)-S7R Cas12i.3.

[0211] FIG10 shows a schematic diagram of the secondary structure of the DR sequence of CasW1. DETAILED DESCRIPTION

[0212] After extensive and in-depth research, the inventors unexpectedly discovered a new gene-editing protein. This gene-editing protein exhibits excellent gene-editing activity, effectively editing or cleaving target genes and treating conditions or diseases in subjects in need. Based on this discovery, the inventors completed the present invention.

[0213] the term

[0214] The following examples are only used to illustrate the present invention, rather than to limit the present invention. Unless otherwise specified, the experiments and methods described in the examples were basically carried out according to conventional methods well known in the art and described in various references.

[0215] In addition, if specific conditions are not specified in the examples, the experiments were performed under conventional conditions or the conditions recommended by the manufacturer. If the manufacturer of the reagents or instruments is not specified, they are all conventional products that can be obtained commercially. It is understood that the examples describe the present invention by way of example and are not intended to limit the scope of the present invention. All publications and other references mentioned herein are incorporated herein by reference in their entirety.

[0216] In order to more easily understand the present disclosure, some terms are first defined. As used in this application, unless otherwise expressly provided herein, each of the following terms should have the meaning given below. Other definitions are set forth throughout the application.

[0217] The term "about" can refer to a value or composition that is within an acceptable error range for a particular value or composition as determined by one of ordinary skill in the art, which will depend in part on how the value or composition is measured or determined. For example, as used herein, the expression "about 100" includes all values ​​between 99 and 101 (e.g., 99.1, 99.2, 99.3, 99.4, etc.).

[0218] As used herein, the terms "comprising" or "including" may be open, semi-closed, or closed. In other words, the terms also include "consisting essentially of" or "consisting of."

[0219] Sequence identity (or homology) is determined by comparing two aligned sequences along a predetermined comparison window (which can be 50%, 60%, 70%, 80%, 90%, 95% or 100% of the length of the reference nucleotide sequence or protein) and determining the number of positions at which identical residues occur. Typically, this is expressed as a percentage. The measurement of sequence identity of nucleotide sequences is a method well known to those skilled in the art.

[0220] gene-editing proteins

[0221] In the present invention, the gene editing protein is the effector protein in the CRISPR / Cas system.

[0222] In the present invention, Cas protein, Cas enzyme, and Cas effector protein can be used interchangeably. Cas protein is taken in its broadest sense, including wild-type Cas protein, its derivatives or variants, analogs, and functional fragments thereof such as oligonucleotide binding fragments.

[0223] The term "wild type" has the meaning generally understood by those skilled in the art, which refers to the typical form of an organism, strain, gene, protein or the characteristics that distinguish it from mutant or variant forms when it exists in nature, which can be isolated from a source in nature and has not been intentionally modified by man.

[0224] The terms "variant," "derivative," and "analog" refer to polypeptides that substantially retain the function or activity of the Cas protein of the present invention.

[0225] Typically, the derivatization of a protein does not adversely affect the desired activity of the protein (e.g., activity binding to a guide RNA, endonuclease activity, activity binding to and cleaving a specific site of a target sequence under the guidance of a guide RNA), that is, the derivative of the protein has the same activity as the protein. Modified forms of "derivatives" include deletions, insertions, modifications, and / or substitutions of one or more amino acids of the protein. The terms "non-naturally occurring" or "engineered" are used interchangeably and indicate artificial involvement.

[0226] In one aspect, the present invention provides a gene editing protein (Cas protein) comprising an amino acid sequence having at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identity to the amino acid sequence of SEQ ID NO. 1, and substantially retains the biological function of the sequence from which it is derived;

[0227] In one embodiment, the amino acid sequence of the Cas protein has one or more amino acid substitutions, deletions, or additions compared to the amino acid sequence of SEQ ID NO. 1, and substantially retains the biological function of the sequence from which it is derived;

[0228] In one embodiment, the Cas protein comprises the amino acid sequence shown in SEQ ID NO.1;

[0229] or a sequence having one or more amino acid substitutions, deletions or additions (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 amino acid substitutions, deletions or additions) compared to the sequence shown in SEQ ID NO. 1; or a sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% amino acid sequence identity to the amino acid sequence shown in SEQ ID NO. 1;

[0230] In one embodiment, the Cas protein has the amino acid sequence shown in SEQ ID NO.1.

[0231] It is clear to those skilled in the art that the structure of a protein can be changed without adversely affecting its activity and functionality, for example, by introducing one or more conservative amino acid substitutions into the amino acid sequence of a protein without adversely affecting the activity and / or three-dimensional structure of the protein molecule.

[0232] Those skilled in the art will appreciate examples and embodiments of conservative amino acid substitutions. Specifically, an amino acid residue can be substituted with another amino acid residue belonging to the same group as the site to be substituted, i.e., a non-polar amino acid residue can be substituted for another non-polar amino acid residue, a polar uncharged amino acid residue can be substituted for another polar uncharged amino acid residue, a basic amino acid residue can be substituted for another basic amino acid residue, and an acidic amino acid residue can be substituted for another acidic amino acid residue. Such substituted amino acid residues may or may not be encoded by the genetic code. As long as the substitution does not result in the inactivation of the biological activity of the protein, conservative substitutions in which one amino acid is replaced by another amino acid belonging to the same group fall within the scope of the present invention. Therefore, the protein of the present invention may contain one or more conservative substitutions in the amino acid sequence, preferably generated by substitution according to Table A. In addition, the present invention also encompasses proteins that also contain one or more other non-conservative substitutions, as long as the non-conservative substitutions do not significantly affect the desired function and biological activity of the protein of the present invention.

[0233] Conservative amino acid replacement can be carried out at one or more predicted non-essential amino acid residues.A "non-essential" amino acid residue is an amino acid residue that can be changed (deleted, substituted or replaced) without changing biological activity, while an "essential" amino acid residue is required for biological activity."Conservative amino acid replacement" is a replacement in which an amino acid residue is replaced by an amino acid residue with a similar side chain. Amino acid replacement can be carried out in the non-conserved region of the Cas enzyme. Generally speaking, such replacement is not carried out on conserved amino acid residues, or on amino acid residues located within a conserved motif, where such residues are required for protein activity. However, it will be appreciated by those skilled in the art that functional variants can have fewer conservative or non-conservative changes in conserved regions.

[0234] Table A

[0235] It is known to those skilled in the art that one or more amino acid residues can be changed (replaced, deleted, truncated or inserted) from the N and / or C terminus of a protein while still retaining its functional activity. Therefore, proteins that have changed one or more amino acid residues from the N and / or C terminus of the Cas protein of the present invention while retaining their desired functional activity are also within the scope of the present invention. These changes may include changes introduced by modern molecular methods such as PCR, which includes PCR amplification of protein coding sequences by means of amino acid coding sequences included in the oligonucleotides used in PCR amplification.

[0236] It will be appreciated that proteins can be altered in a variety of ways, including amino acid substitutions, deletions, truncations, and insertions, and methods for such manipulations are generally known to those skilled in the art.

[0237] For example, amino acid sequence variants of Cas proteins can be prepared by mutation of DNA. It can also be accomplished by other forms of mutagenesis and / or by directed evolution, for example, using known mutagenesis, recombination and / or shuffling methods, combined with relevant screening methods, to perform one or more amino acid substitutions; or one to multiple amino acid deletions and / or one to multiple amino acid insertions.

[0238] It will be appreciated by those skilled in the art that these minor amino acid changes in the Cas proteins of the present invention can occur (e.g., naturally occurring mutations) or be generated (e.g., using r-DNA technology) without loss of protein function or activity. If these mutations occur in the catalytic domain, active site, or other functional domains of the protein, the properties of the polypeptide may be altered, but the polypeptide may retain its activity. If the mutations present are not close to the catalytic domain, active site, or other functional domains, then the effect can be expected to be less.

[0239] Those skilled in the art can identify the essential amino acids of the Cas protein according to methods known in the art, such as site-directed mutagenesis or protein evolution or analysis of bioinformatics systems. The catalytic domain, active site or other functional domain of the protein can also be determined by physical analysis of the structure, such as by the following techniques: such as nuclear magnetic resonance, crystallography, electron diffraction or photoaffinity labeling, combined with mutations of amino acids at putative key sites.

[0240] Orthologue (ortholog)

[0241] As used herein, the term "orthologue" has the meaning commonly understood by those skilled in the art. As a further guide, an "orthologue" of a protein as described herein refers to a protein belonging to a different species that performs the same or similar function as the protein to which it is an orthologue.

[0242] The nucleic acid cleavage disclosed herein includes: DNA or RNA breakage in the target nucleic acid produced by the Cas protein (Cis cleavage), and DNA or RNA breakage in a side branch nucleic acid substrate (single-stranded nucleic acid substrate) caused by the Cas protein side cutting activity (i.e., non-specific or non-targeted, Trans cleavage). In some embodiments, the cleavage is a double-stranded DNA break. In some embodiments, the cleavage is a single-stranded DNA break or a single-stranded RNA break.

[0243] Trans cutting refers to that in certain environments, the activated Cas12 family protein remains active after binding to the target sequence, and continues to non-specifically cut non-target oligonucleotides. The lateral cutting activity can detect the presence of specific target oligonucleotides using the Cas system. For example, the Cas12i system is engineered to non-specifically cut ssDNA or transcripts. The lateral cutting activity is used for a highly sensitive and specific nucleic acid detection platform called SHERLOCK, which can be used for many clinical diagnoses (Gootenberg, JS et al., Nucleic acid detection with CRISPR-Cas13a / C2c2. Science 356, 438-442 (2017)).

[0244] Fusion protein

[0245] In one aspect, the present invention provides a fusion protein comprising the Cas protein described in any one of the foregoing and one or more functional domains.

[0246] In one embodiment, the functional domain comprises one or more of a localization signal, a reporter protein, a Cas protein targeting portion, a DNA binding domain, an epitope tag, a transcription activation domain, a transcription repression domain, a nuclease, a deamination domain, a methylase, a demethylase, a transcription release factor, an HDAC, a cleavage-active polypeptide, and a ligase;

[0247] In one embodiment, "methylase" is exemplified by HhaI DNA m5c-methyltransferase (M.HhaI), DNA methyltransferase 1 (DNMT1), DNA methyltransferase 3a (DNMT3a), DNA methyltransferase 3b (DNMT3b), METI, DRM3, ZMET2, CMT1, CMT2, etc.

[0248] "Demethylase" refers to an enzyme that removes methyl (CH3-) groups from nucleic acids, proteins (e.g., histones) and other molecules. Demethylases are important in epigenetic modification mechanisms. Demethylase proteins change the transcriptional regulation of the genome by controlling the methylation levels that occur on DNA and histones, and then regulate the chromatin state at specific loci in the organism, such as TET1 (ten-eleven translocation 1), ten-eleven translocation (TET) dioxygenase 1 (TET1CD), DME, DML1, DML2, ROS1, etc.

[0249] In another preferred embodiment, the transcriptional release factor, for example, is eukaryotic release factor 1 (ERF1) activity or eukaryotic release factor 3 (ERF3).

[0250] In one embodiment, the functional domain is selected from the group consisting of an adenosine deaminase catalytic domain or a cytidine deaminase catalytic domain.

[0251] In one embodiment, the localization signal comprises a nuclear localization signal and / or a nuclear export signal;

[0252] Preferably, the nuclear export signal comprises human protein tyrosine kinase 2;

[0253] Preferably, the reporter protein comprises one or more of glutathione-S-transferase, horseradish peroxidase, chloramphenicol acetyltransferase, β-galactosidase, β-glucuronidase or autofluorescent protein;

[0254] Preferably, the autofluorescent protein includes one or more of green fluorescent protein, HcRed, DsRed, cyan fluorescent protein, yellow fluorescent protein or blue fluorescent protein;

[0255] Preferably, the DNA binding domain comprises one or more of methylation binding protein, LexADBD or Gal4DBD;

[0256] Preferably, the epitope tag comprises one or more of a histidine tag, a V5 tag, a FLAG tag, an influenza virus hemagglutinin tag, a Myc tag, a VSV-G tag or a thioredoxin tag;

[0257] Preferably, the transcriptional activation domain comprises VP64 and / or VPR;

[0258] Preferably, the transcriptional repression domain comprises KRAB and / or SID;

[0259] Preferably, the nuclease comprises FokI;

[0260] Preferably, the deamination domain comprises one or more of ADAR1, ADAR2, APOBEC, AID or TAD;

[0261] Preferably, the cleavage active polypeptide includes a polypeptide having single-stranded RNA cleavage activity, a polypeptide having double-stranded RNA cleavage activity, a polypeptide having single-stranded DNA cleavage activity or a polypeptide having double-stranded DNA cleavage activity;

[0262] Preferably, the ligase comprises DNA ligase and / or RNA ligase.

[0263] In one embodiment, the functional domain is the full length or functional fragment of TadA8e.

[0264] polynucleotides

[0265] In one aspect, the present invention provides a polynucleotide, which is a polynucleotide sequence encoding the gene editing protein (Cas protein) or a polynucleotide sequence encoding the aforementioned fusion protein.

[0266] In one embodiment, the polynucleotide (DNA molecule) comprises nucleotides that are more than 70%, preferably more than 90%, more preferably more than 95%, further preferably 99%, and further preferably 100% identical to the nucleotide sequence described in SEQ ID NO.2.

[0267] In one embodiment, the polynucleotide is a DNA molecule that is codon-optimized according to the codon preference of the host cell.

[0268] The optimization described in the present disclosure may require mutations in the nucleotide sequence of the coded protein (e.g., Cas protein of the present disclosure) to simulate the codon preference of the expected host organism or cell when encoding the same protein at the same time. Therefore, the codons can be changed, but the encoded protein remains unchanged. For example, if the expected target cell is a human cell, a nucleotide sequence of the coded protein optimized by human codons can be used. As another non-limiting embodiment, if the expected host cell is an animal cell (e.g., mouse cell, insect cell), the nucleotide sequence of the coded protein optimized by the animal codon can be generated. As another non-limiting embodiment, if the expected host cell is a plant cell, the nucleotide sequence of the coded protein optimized by plant codons can be generated.

[0269] A selection list of codons is readily available, for example, the "Codon Usage Database" available at www.kazusa.or.jp / codon. In some cases, the nucleic acids of the present disclosure comprise nucleotide sequences encoding CasY7 or its variants or its fusion proteins, which are codon-optimized for expression in eukaryotic cells. In some cases, the nucleic acids of the present disclosure comprise nucleotide sequences encoding CasW1 or its variants or its fusion proteins, which are codon-optimized for expression in animal cells. In some cases, the nucleic acids of the present disclosure comprise nucleotide sequences encoding CasW1 or its variants or its fusion proteins, which are codon-optimized for expression in fungal cells. In some cases, the nucleic acids of the present disclosure comprise nucleotide sequences encoding CasW1 or its variants or its fusion proteins, which are codon-optimized for expression in plant cells.

[0270] In one embodiment, the host cell comprises a prokaryotic cell or a eukaryotic cell.

[0271] CRISPR system

[0272] The terms “clustered regularly interspaced short palindromic repeats (CRISPR)-CRISPR-associated (Cas) (CRISPR-Cas) system” or “CRISPR system” are used interchangeably and have the meaning commonly understood by those skilled in the art, which generally includes transcripts or other elements associated with the expression of CRISPR-associated (“Cas”) genes, or transcripts or other elements capable of directing the activity of the Cas genes.

[0273] CRISPR-Cas Composition

[0274] In one aspect, the present invention also provides a CRISPR-Cas composition, comprising:

[0275] (1) Protein component: the aforementioned gene editing protein (Cas protein), or the aforementioned fusion protein; or a nucleic acid molecule encoding the gene editing protein (Cas protein) or the aforementioned fusion protein;

[0276] (2) RNA component: guide RNA, or one or more nucleic acids encoding the guide RNA, or a precursor RNA of the guide RNA, or a nucleic acid encoding a precursor RNA of the guide RNA;

[0277] The protein component and the nucleic acid component combine with each other to form a complex.

[0278] In one embodiment, the composition is an activated CRISPR complex, further comprising: a target sequence of a target nucleic acid bound to the guide RNA.

[0279] In one embodiment, the CRISPR-Cas composition comprises one or more vectors, wherein the one or more vectors comprise:

[0280] (1) a first regulatory element, which is operably linked to a nucleotide sequence encoding the gene editing protein (Cas protein) or a nucleotide sequence encoding the fusion protein; and

[0281] (2) a second regulatory element, the second regulatory element being operably linked to a nucleotide sequence encoding the guide RNA, wherein the guide RNA comprises:

[0282] (a) a spacer sequence capable of hybridizing to a target sequence of a target nucleic acid, and

[0283] (b) a direct repeat (DR) sequence connected to the spacer sequence that can guide the gene editing protein (Cas protein) to bind to the guide RNA to form a CRISPR-Cas complex targeting the target sequence;

[0284] The first regulatory element and the second regulatory element are located on the same or different vectors of the CRISPR-Cas vector system.

[0285] In one embodiment, the first regulatory element or the second regulatory element comprises a promoter, and the promoter comprises one or more of an inducible promoter, a constitutive promoter, or a tissue-specific promoter;

[0286] In one embodiment, the promoter comprises one or more of T7, SP6, T3, CMV, EF1a, SV40, PGK1, human β-actin, CAG, U6, H1, T7, T7lac, araBAD, trp, lac, or Ptac;

[0287] In one embodiment, the first regulatory element and the second regulatory element are located on the same or different vectors.

[0288] In one embodiment, the vector comprises a retroviral vector, a lentiviral vector, an adenoviral vector, an adeno-associated viral vector, a herpes simplex vector, or a phagemid vector;

[0289] In one embodiment, the vector comprises a plasmid vector.

[0290] In one embodiment, the target nucleic acid comprises DNA derived from a eukaryote or DNA derived from a prokaryote;

[0291] In one embodiment, the eukaryotic organism includes an animal or a plant;

[0292] In one embodiment, the target nucleic acid comprises non-human mammalian DNA, human DNA, insect DNA, bird DNA, reptile DNA, amphibian DNA, rodent DNA, fish DNA, worm DNA, nematode DNA, or yeast DNA;

[0293] In one embodiment, the non-human mammalian DNA comprises non-human primate DNA.

[0294] CRISPR / Cas complex

[0295] The term "CRISPR / Cas complex" refers to a complex formed by the binding of guide RNA, gRNA (guide RNA) or mature crRNA (or guide RNA) to a gene editing protein (Cas protein), which contains a direct repeat sequence that hybridizes to the guide sequence of the target sequence and binds to the gene editing protein (Cas protein). The complex can recognize and cut the target nucleotide that can hybridize with the guide RNA or mature crRNA.

[0296] guide RNA (gRNA)

[0297] The terms "guide RNA (gRNA)", "mature crRNA", "crRNA", "guide sequence", and "guide RNA" are used interchangeably and have the meanings commonly understood by those skilled in the art. Generally speaking, a guide RNA can comprise a direct repeat (DR) sequence and a spacer sequence, or consist essentially of or consist of a direct repeat (DR) sequence and a spacer sequence.

[0298] In some cases, the spacer sequence is any polynucleotide sequence that has sufficient complementarity with the target sequence to hybridize with the target sequence and guide the CRISPR-Cas complex to specific binding to the target sequence. In one embodiment, when optimally aligned, the degree of complementarity between the spacer sequence and its corresponding target sequence is at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, or at least 99%. The guide sequence comprises a sequence (e.g., a direct repeat (DR) sequence) that has sufficient complementarity with the target nucleic acid sequence to hybridize with the target nucleic acid sequence and guide the sequence-specific binding of the complex to the target nucleic acid sequence.

[0299] It is known in the art that complete complementarity is not required on the basis of sufficient complementarity to function, and therefore, if necessary, the cleavage efficiency can be adjusted by introducing mismatches (e.g., one or more mismatches between the spacer sequence and the target nucleic acid, such as 1 or 2 nucleotide mismatches (including the position of the mismatch along the spacer sequence / target sequence). For example, if a cleavage rate of less than 100% of the target is desired (e.g., in a cell population), 1 or 2 mismatches between the spacer sequence and the target sequence can be introduced into the spacer sequence.

[0300] In one aspect, the present invention provides a guide RNA, comprising a direct repeat (DR) sequence capable of binding to the Cas protein and a spacer sequence capable of targeting a target sequence.

[0301] In one embodiment, the direct repeat sequence, the direct repeat sequence (Direct Repeat, DR) comprises the sequence shown in SEQ ID NO.3.

[0302] In one embodiment, the 3' end of the direct repeat sequence comprises a stem-loop structure, further comprising a first stem nucleotide chain and a second stem nucleotide chain hybridized to form a stem of the stem-loop structure, and the loop nucleotide chain forms a loop of the stem-loop structure;

[0303] In one embodiment, the direct repeat sequence comprises a nucleotide sequence having at least 80% identity with the nucleotide sequence described in SEQ ID NO. 3;

[0304] In one embodiment, the direct repeat sequence comprises a nucleotide sequence having at least 85% or more, more preferably 90% or more, and even more preferably 95% or more identity with the nucleotide sequence described in SEQ ID NO. 3;

[0305] In one embodiment, the direct repeat sequence comprises the nucleotide sequence described in SEQ ID NO.3.

[0306] In one embodiment, more than 80% of the spacer sequence is complementary to the target nucleic acid;

[0307] In one embodiment, more than 90%, more preferably more than 95%, further preferably more than 99%, and even more preferably 100% of the spacer sequence is complementary to the target nucleic acid;

[0308] In one embodiment, the length of the spacer sequence is 18-41 nt, for example 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41 nt, more preferably 18 to 27 nucleotides, more preferably 18 to 24 nucleotides, most preferably 18 to 22 nucleotides.

[0309] In one embodiment, the spacer sequence is 20 nt in length.

[0310] Target nucleic acid

[0311] In the present invention, target nucleic acid is used interchangeably with target sequence or target nucleic acid sequence or target nucleic acid molecule, and refers to a specific nucleic acid comprising a nucleic acid sequence that is fully or partially complementary to the spacer sequence in the guide RNA. "Target sequence" refers to a polynucleotide targeted by the spacer sequence in the guide RNA, such as a sequence complementary to the spacer sequence, wherein the hybridization between the target sequence and the spacer sequence will promote the formation of a CRISPR-Cas complex (including Cas protein and guide RNA). Complete complementarity is not required, as long as there is enough complementarity to cause hybridization and promote the formation of a CRISPR-Cas complex. In some embodiments, the target nucleic acid comprises a non-coding region (e.g., a promoter or terminator). In some embodiments, the target nucleic acid is single-stranded, or double-stranded.

[0312] The target sequence can comprise any polynucleotide, such as DNA. In some cases, the target sequence is located within or outside the cell. In some cases, the target sequence is located within the nucleus, cytoplasm, or organelle (e.g., mitochondria or chloroplast) of the cell.

[0313] The target nucleic acid can be a sequence encoding a gene product (e.g., a protein) or a non-coding sequence (e.g., a regulatory polynucleotide or junk DNA). In some cases, the target sequence should be associated with a protospacer adjacent motif (PAM).

[0314] Donor template

[0315] In the present invention, donor template nucleic acid or donor template are used interchangeably to refer to a nucleic acid molecule that can be used by one or more cellular proteins to change the structure of the target nucleic acid after the gene editing protein (Cas protein) described herein changes the target nucleic acid.

[0316] In certain embodiments, the donor template nucleic acid is a double-stranded nucleic acid or a single-stranded nucleic acid. In certain embodiments, the donor template nucleic acid is a linear or circular (e.g., a plasmid). In certain instances, the donor template nucleic acid is an exogenous nucleic acid molecule. In certain instances, the donor template nucleic acid is an endogenous nucleic acid molecule (e.g., a chromosome). In certain embodiments, the donor template can be utilized to realize genetic recombination, and this recombination is homologous recombination.

[0317] Cutting

[0318] Cutting refers to the DNA breakage in the target nucleic acid produced by the gene editing proteins (Cas proteins) described herein. In some embodiments, cutting is a double-stranded DNA break. In some embodiments, cutting is a single-stranded DNA break.

[0319] In the present invention, the meanings of cleaving a target nucleic acid and modifying a target nucleic acid may overlap. Modifying a target nucleic acid includes not only modification of a single nucleotide but also insertion or deletion of a nucleic acid fragment.

[0320] Reporter nucleic acid

[0321] Reporter nucleic acid refers to a molecule that can be cut or otherwise deactivated by an activated CRISPR system protein as described herein. Reporter nucleic acid comprises a nucleic acid element that can be cut by a CRISPR protein (e.g., using a single-stranded non-targeted nucleic acid molecule, each of which includes different reporter groups or labeling molecules at both ends). The cutting of the nucleic acid element produces a detectable signal. Before cutting, or when the reporter nucleic acid is in an "active" state, the reporter nucleic acid prevents the generation or detection of a positive detectable signal. It will be understood that in certain example embodiments, a minimum background signal can be generated in the presence of active reporter nucleic acid. A positive detectable signal can be any signal that can be detected using optical, fluorescent, chemiluminescent, electrochemical, or other detection methods known in the art. For example, in certain embodiments, when there is a reporter nucleic acid, a first signal (i.e., a negative detectable signal) can be detected, which is then converted to a second signal (e.g., a positive detectable signal) after detecting the target molecule and cutting or deactivating the activated CRISPR protein. The reporter nucleic acid can be a single-stranded DNA molecule, a single-stranded RNA molecule, or a single-stranded DNA-RNA hybrid.

[0322] The detection method of the present invention can be used for quantitative detection of target nucleic acids. The quantitative detection index can be quantified based on the signal strength of the reporter group, such as the luminescence intensity of the fluorescent group, or the width of the color band.

[0323] Functional domain

[0324] The functional domain herein is taken in its broadest sense, including proteins such as enzymes or factors themselves or having specific functional fragments / domains. A gene editing protein (e.g., a dCas protein) is connected / concluded with one or more functional domains, which are selected from one or more of a positioning signal, a reporter protein, a Cas protein targeting portion, a DNA binding domain, an epitope tag, a transcription activation domain, a transcription repression domain, a nuclease, a deamination domain, a methylase, a demethylase, a transcription release factor, an HDAC, a cleavage active polypeptide, and a ligase. When more than one functional domain is included, the functional domains may be the same or different.

[0325] Deamination domain

[0326] In the present invention, the deamination domain includes a deaminase (e.g., an adenosine deaminase or a cytidine deaminase) catalytic domain. As used herein, "adenosine deaminase" or "adenosine deaminase protein" refers to a protein, a polypeptide, or one or more functional domains of a protein or polypeptide that is capable of catalyzing the hydrolytic deamination reaction of converting adenine (or the adenine portion of a molecule) to hypoxanthine (or the hypoxanthine portion of a molecule).

[0327] In some embodiments, the adenine-containing molecule is adenosine (A), and the hypoxanthine-containing molecule is inosine (I). The adenine-containing molecule can be deoxyribonucleic acid (DNA) or ribonucleic acid (RNA).

[0328] Adenosine deaminases include, but are not limited to, members of the enzyme family known as adenosine deaminases acting on RNA (ADARs), members of the enzyme family known as adenosine deaminases acting on tRNA (ADATs), and other family members containing adenosine deaminase domains (ADADs). According to the present disclosure, adenosine deaminases are capable of targeting adenine in RNA / DNA and RNA duplexes. In specific embodiments, adenosine deaminases have been modified to increase their ability to edit DNA in RNA / DNA heteroduplexes of RNA duplexes.

[0329] In some embodiments, the deaminase is a cytidine deaminase. The term "cytidine deaminase" or "cytidine deaminase protein" refers to a protein, polypeptide, or one or more functional domains of a protein or polypeptide that can catalyze the hydrolytic deamination reaction of cytosine (or the cytosine portion of a molecule) into uracil (or the uracil portion of a molecule). In some embodiments, the cytosine-containing molecule is cytidine (C), and the uracil-containing molecule is uridine (U). The cytosine-containing molecule can be deoxyribonucleic acid (DNA) or ribonucleic acid (RNA).

[0330] Cytidine deaminases include, but are not limited to, members of the enzyme family known as apolipoprotein B mRNA editing complex (APOBEC) family deaminases, activation-induced deaminases (AID), or cytidine deaminase 1 (CDA1). In a specific embodiment, an APOBEC family deaminase is included.

[0331] In some embodiments, the cytidine deaminase comprises the wild-type amino acid sequence of cytidine deaminase. In some embodiments, the cytidine deaminase comprises one or more mutations in the cytidine deaminase sequence such that the editing efficiency and / or substrate editing preference of the cytidine deaminase is altered according to specific needs.

[0332] Identity

[0333] "Identity" refers to the matching of sequences between two polypeptides or between two nucleic acids. "Identity" represents the percentage of residues that are identical between the polypeptide or nucleic acid sequences, and is calculated based on the total number of residues determined by the type of mutation. Mutation types include insertions (extensions) at either or both ends of the sequence, deletions (truncations) at either or both ends of the sequence, substitutions / alternations of one or more amino acids / nucleotides, insertions within the sequence, and deletions within the sequence.

[0334] Taking polypeptide sequences as an example, if the mutation type is one or more of the following: replacement / substitution of one or more amino acids / nucleotides, insertion within the sequence, and deletion within the sequence, the total number of residues is calculated based on the larger of the compared molecules. If the mutation type also includes insertions (extensions) at either or both ends of the sequence or deletions (truncations) at either or both ends of the sequence, the number of amino acids inserted or deleted at either or both ends (for example, the number of insertions or deletions at both ends is less than 20) is not included in the total number of residues. When calculating the percent identity, the sequences being compared are aligned in a manner that produces the maximum match between the sequences, and gaps in the alignment (if any) are resolved using a specific algorithm. The same applies to nucleotide identity calculations.

[0335] carrier

[0336] A vector is a nucleic acid molecule capable of transporting another nucleic acid molecule to which it has been linked.

[0337] Vectors include, but are not limited to, single-stranded, double-stranded, or partially double-stranded nucleic acid molecules; nucleic acid molecules comprising one or more free ends, or no free ends (e.g., circular); nucleic acid molecules comprising DNA, RNA, or both; and other various polynucleotides known in the art. Vectors can be introduced into host cells by transformation, transduction, or transfection so that the genetic material elements they carry are expressed in the host cells. A vector can be introduced into a host cell to produce transcripts, proteins, or peptides, including proteins, fusion proteins, isolated nucleic acid molecules, etc. as described herein (e.g., CRISPR transcripts, such as nucleic acid transcripts, proteins, or enzymes). A vector can contain a variety of elements that control expression, including, but not limited to, promoter sequences, transcription initiation sequences, enhancer sequences, selection elements, and reporter genes. The vector may also contain a replication initiation site.

[0338] The term "vector" refers to a plasmid or viral vector, wherein the plasmid is a circular double-stranded DNA loop that can be inserted into another DNA fragment by, for example, standard molecular cloning techniques. Viral vectors include virally derived DNA or RNA sequences that are present in vectors for packaging viruses, and viruses include, for example, retroviruses, replication-defective retroviruses, adenoviruses, replication-defective adenoviruses, and adeno-associated viruses. Viral vectors also include polynucleotides carried by viruses for transfection into a host cell. Some vectors (for example, bacterial vectors and episomal mammalian vectors with bacterial origins of replication) can replicate autonomously in the host cells into which they are introduced.

[0339] Other vectors (e.g., non-episomal mammalian vectors) are integrated into the genome of the host cell upon introduction into the host cell and are replicated together with the host genome. Furthermore, some vectors are capable of directing the expression of genes to which they are operably linked. Such vectors are referred to as "expression vectors."

[0340] In some embodiments, the vector (e.g., a viral vector or a non-viral vector, such as a lentiviral vector or a plasmid) can be delivered to the target tissue by, for example, intramuscular injection, intravenous administration, transdermal administration, intranasal administration, oral administration, or mucosal administration. The above-mentioned delivery can be carried out via a single dose or multiple doses. It will be understood by those skilled in the art that the actual dose to be delivered herein can vary to a large extent according to a variety of factors, including but not limited to vector selection, target cells, organisms, tissues, the general condition of the subject to be treated, the degree of transformation / modification sought, the route of administration, the mode of administration, and the type of transformation / modification sought.

[0341] Regulatory elements

[0342] As used herein, "regulatory elements" include promoters, enhancers, internal ribosome entry sites (IRES), and other expression control elements (e.g., transcription termination signals, such as polyadenylation signals, poly-U sequences), which are described in detail in Goeddel, GENE EXPRESSION TECHNOLOGY: METHODS IN ENZYMOLOGY 185, Academic Press, San Diego, Calif (1990). In some cases, regulatory elements include those that direct the constitutive expression of a nucleotide sequence in many types of host cells and those that direct the expression of the nucleotide sequence only in certain host cells (e.g., tissue-specific regulatory sequences). Tissue-specific promoters can primarily direct expression in the desired tissue of interest, such as muscle, neurons, bone, skin, blood, specific organs (e.g., liver, pancreas), or special cell types (e.g., lymphocytes). In other cases, regulatory elements can also direct expression in a temporally dependent manner (e.g., in a cell cycle-dependent or developmental stage-dependent manner), which may or may not be tissue- or cell-type specific.

[0343] The term "promoter" refers to a non-coding nucleotide sequence located upstream of a gene that can initiate expression of downstream genes. A constitutive promoter is a nucleotide sequence that, when operably linked to a polynucleotide encoding or limiting a gene product, will result in the production of a gene product in the cell under most or all physiological conditions of the cell. An inducible promoter refers to a promoter that selectively expresses a coding sequence or functional RNA in response to the presence of endogenous or exogenous stimuli, such as by responding to chemical compounds (chemical inducers), or to environmental, hormone, chemical, and / or developmental signals. Inducible or regulated promoters include promoters that are induced or regulated, for example, by light, heat, stress, flooding or drought, salt stress, osmotic stress, plant hormones, wounds, or chemicals (such as ethanol, abscisic acid (ABA), jasmonate, salicylic acid, or safeners).

[0344] host cells

[0345] As used herein, "host cell" refers to a eukaryotic cell (e.g., an animal cell, a plant cell, a fungal cell, etc.), a prokaryotic cell (e.g., some microbial cells, Escherichia coli, Bacillus subtilis, etc.), or a cell from a multicellular organism cultured as a unicellular entity (e.g., a cell line), which serves as a recipient of nucleic acid (e.g., an expression vector) and includes descendants of the original cell that has been genetically modified by the nucleic acid.

[0346] It is understood that the progeny of a single cell may not necessarily have completely the same morphology, genome, etc. as the original parent cell due to natural, accidental, or deliberate mutation. A "recombinant host cell" (also called a "genetically modified host cell") is a host cell into which a heterologous nucleic acid, such as an expression vector, has been introduced.

[0347] Those skilled in the art will appreciate that the design of the expression vector may depend on factors such as the choice of the host cell to be transformed, the level of expression desired, and the like.

[0348] In another aspect, the present invention also provides a host cell or its progeny, wherein the host cell comprises the aforementioned gene editing protein (Cas protein), or the aforementioned fusion protein, or the aforementioned polynucleotide, or the aforementioned vector system, or the aforementioned CRISPR-Cas system, or the aforementioned composition.

[0349] In one embodiment, the host cell comprises a non-human mammal, human, insect, bird, reptile, amphibian, rodent, fish, worm, nematode, or yeast cell.

[0350] In one aspect, the present invention also provides a multicellular organism comprising the aforementioned cell or its progeny.

[0351] In one embodiment, the multicellular organism is an animal model or a plant model for a relevant disease.

[0352] NLS

[0353] NLS refers to "nuclear localization sequence" or "nuclear localization signal," which refers to an amino acid sequence that promotes protein entry into the cell nucleus. Nuclear localization sequences are known in the art (e.g., described in International PCT Application PCT / EP2000 / 011690, filed by Plank et al. on November 23, 2000, and published as WO / 2001 / 038547 on May 31, 2001), which is incorporated herein by reference for its disclosure of exemplary nuclear localization sequences. In other embodiments, the NLS is an optimized NLS, such as described in Koblan et al., Nature Biotech. 2018 doi: 10.1038 / nbt.4172.

[0354] operably connected

[0355] "Operably linked" means that the nucleotide sequence of interest is linked to regulatory elements in a manner that allows expression of the nucleotide sequence (e.g., in an in vitro transcription / translation system or in a host cell when the vector is introduced into the host cell). Advantageous vectors include lentiviruses and adeno-associated viruses, and the type of these vectors can also be selected to target specific cell types.

[0356] complementary

[0357] "Complementarity" refers to the ability of one nucleic acid sequence to form one or more hydrogen bonds with another nucleic acid sequence using traditional Watson-Crick or other non-traditional types. Percent complementarity represents the percentage of residues in one nucleic acid molecule that can form hydrogen bonds (e.g., Watson-Crick base pairing) with another nucleic acid sequence (e.g., 5, 6, 7, 8, 9, or 10 out of 10 are complementary, resulting in percentages of 50%, 60%, 70%, 80%, 90%, and 100%). "Complete complementarity" means that all consecutive residues of one nucleic acid sequence form hydrogen bonds with the same number of consecutive residues in another nucleic acid sequence. "Substantially complementary" refers to a degree of complementarity that is at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 97%, 98%, 99% or 100% over a region of 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 30, 35, 40, 45, 50 or more nucleotides, or to two nucleic acids that hybridize under stringent conditions.

[0358] The term "stringent conditions" in relation to hybridization refers to conditions under which a nucleic acid having complementarity with a target sequence predominantly hybridizes to the target sequence and substantially does not hybridize to non-target sequences. Stringent conditions are generally sequence-dependent and depend on many factors. Generally speaking, the longer the sequence, the higher the temperature at which it will specifically hybridize to its target sequence.

[0359] "Hybridization" refers to a reaction in which one or more polynucleotides react to form a complex that is stabilized via hydrogen bonding of the bases between the nucleotide residues. The complex may comprise two strands forming a duplex, three or more strands forming a multi-stranded complex, a single self-hybridizing strand, or any combination of these. A hybridization reaction may constitute one step in a broader process, such as the initiation of PCR, or the cleavage of a polynucleotide by an enzyme. A sequence capable of hybridizing to a given sequence is referred to as the "complement" of that given sequence.

[0360] Hybridization of the target sequence with the gRNA indicates that at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% of the nucleic acid sequences of the target sequence and the gRNA can hybridize to form a complex; or represents that at least 12, 15, 16, 17, 18, 19, 20 or more bases of the nucleic acid sequences of the target sequence and the gRNA can complement each other and hybridize to form a complex.

[0361] Express

[0362] Nucleic acid expression includes one or more of production of an RNA template from a DNA sequence (e.g., transcription), processing of the RNA transcript (e.g., by splicing, editing, 5' capping, and / or 3' end processing), translation of the RNA into a polypeptide or protein, or post-translational modification of the polypeptide or protein.

[0363] deliver

[0364] "Delivery" refers to providing an entity (such as a drug) to a destination. For example, the components of the CRISPR-Cas system / composition of the present invention can be delivered in various forms, such as a combination of DNA / RNA or RNA / RNA or protein RNA. For example, a gene editing protein (Cas protein) can be delivered as a polynucleotide encoding DNA or a polynucleotide encoding RNA or as a protein.

[0365] In one aspect, the present invention also provides a delivery system, which comprises the gene editing protein (Cas protein) or the fusion protein, or the polynucleotide, or the CRISPR-Cas composition.

[0366] In one embodiment, the delivery system further comprises a delivery vehicle, and the delivery vehicle comprises nanoparticles, liposomes, exosomes, microbubbles, a gene gun, or an electroporation device.

[0367] In addition, when the delivery object is a plant cell, a method such as cell penetrating peptide (CPP) delivery is also adopted. For example, in one embodiment, a gene editing protein (Cas protein) and / or at least one guide RNA is coupled to one or more CPPs, thereby effectively transporting the CPP coupled with the gene editing protein (Cas protein) and / or the guide RNA into the plant cell (e.g., in the protoplast). CPP has a short peptide of less than 35 amino acids, which is derived from a protein or derived from a chimeric sequence and can transport biomolecules across the cell membrane in a non-receptor-dependent manner. CPP can be a cationic peptide, a peptide with a hydrophobic sequence, an amphipathic peptide, a peptide rich in proline and an antimicrobial sequence, and a chimeric or dichotomous peptide. CPP can penetrate the biomembrane and therefore trigger different biomolecules to move across the cell membrane into the cytoplasm, and can improve their intracellular pathways, and therefore promote the interaction between biomolecules and targets.

[0368] Exemplary CPPs include Tat (a nuclear transcription activator protein required for viral replication by HIV type 1), penetratin, Kaposi fibroblast growth factor (FGF) signal peptide sequence, integrin β3 signal peptide sequence, polyarginine peptide Arg sequence, guanine-rich molecule transporter, sweet arrow peptide, etc.

[0369] connector

[0370] As used herein, "linker" refers to a chemical group or molecule that connects two molecules or moieties, such as two domains of a fusion protein, such as a gene editing protein (Cas protein) and a deaminase. In some connection methods, the linker is located between or flanking two groups, molecules, or other moieties and connects the two by a covalent bond.

[0371] In some embodiments, the linker is a linear polypeptide formed by amino acids or multiple amino acid residues connected by peptide bonds. In some embodiments, the linker is an organic molecule, group, polymer or chemical moiety. The length and type of the linker can be designed as needed. In some embodiments, the linker can be selected from artificially synthesized amino acid sequences or naturally occurring polypeptide sequences.

[0372] Detection

[0373] In one aspect, the present invention also provides a method for targeting and editing a target nucleic acid, comprising contacting the target nucleic acid with any one of the aforementioned CRISPR-Cas systems or compositions.

[0374] In one aspect, the present invention also provides a method for non-specifically degrading single-stranded DNA after recognizing a target nucleic acid, the method comprising contacting the target nucleic acid with the aforementioned CRISPR-Cas composition.

[0375] In one aspect, the present invention also provides a method for targeting a non-spacer complementary strand of a double-stranded target nucleic acid and causing a nick therein after recognizing a spacer complementary strand of the double-stranded target nucleic acid, the method comprising contacting the double-stranded target nucleic acid with the aforementioned CRISPR-Cas system or composition.

[0376] In one aspect, the present invention also provides a method for targeting and cleaving a double-stranded target nucleic acid, comprising contacting the double-stranded target nucleic acid with the aforementioned CRISPR-Cas system or composition.

[0377] In one embodiment, the non-spacer sequence complementary strand of the double-stranded target nucleic acid is nicked before the spacer complementary strand of the double-stranded DNA is nicked.

[0378] In one aspect, the present invention also provides a method for specifically editing a double-stranded nucleic acid, the method comprising contacting the following under sufficient conditions and for a sufficient amount of time,

[0379] (1) the aforementioned gene editing protein (Cas protein), or fusion protein, another enzyme with sequence-specific nicking activity, and the guide RNA, wherein the guide RNA guides the gene editing protein (Cas protein) or the fusion protein to produce a nick on the relative chain relative to the activity of the other sequence-specific nicking enzyme; and (2) the double-stranded nucleic acid; the method results in the formation of a double-strand break.

[0380] In one aspect, the present invention also provides a method of editing a double-stranded nucleic acid, the method comprising contacting the following under sufficient conditions and for a sufficient amount of time:

[0381] (1) the aforementioned gene editing protein (Cas protein), or a fusion protein, and a fusion protein of a protein domain having DNA modification activity, and the RNA guide targeting the double-stranded nucleic acid; and (2) the double-stranded nucleic acid;

[0382] The gene editing protein (Cas protein) of the fusion protein is modified to produce a nick in the non-target strand of the double-stranded nucleic acid.

[0383] In one embodiment, the two strands of the double-stranded nucleic acid are cleaved at different sites, resulting in staggered cleavage.

[0384] In one embodiment, both strands of the double-stranded nucleic acid are cleaved at the same site, resulting in a blunt double-strand break.

[0385] In one aspect, the present invention also provides a method for targeting and cleaving a single-stranded target nucleic acid, the method comprising contacting the target nucleic acid with any one of the aforementioned CRISPR-Cas compositions.

[0386] In one aspect, the present invention also provides a method for inducing a change in cell state, comprising contacting the aforementioned CRISPR-Cas composition with the target nucleic acid in the cell.

[0387] In one embodiment, the cell state comprises apoptosis or quiescence;

[0388] In one embodiment, the cell comprises a eukaryotic cell or a prokaryotic cell;

[0389] In one embodiment, the cell comprises a mammalian cell or a plant pathogenic cell;

[0390] In one embodiment, the cell comprises a cancer cell;

[0391] In one embodiment, the cell comprises an infectious cell or a cell infected by an infectious agent;

[0392] In one embodiment, the cells include virus-infected cells and prion-infected cells;

[0393] In one embodiment, the cell comprises a fungal cell, a protozoan, or a parasite cell.

[0394] In one aspect, the present invention also provides a method for detecting a target nucleic acid in a sample, the method comprising contacting the sample with the aforementioned gene editing protein (Cas protein), a guide RNA, and a non-target sequence; detecting a detectable signal generated by the gene editing protein (Cas protein) cutting the non-target sequence, thereby detecting the target nucleic acid; the non-target sequence does not hybridize with the guide RNA.

[0395] Reagent test kit

[0396] In one aspect, the present invention provides a kit comprising the aforementioned gene editing protein (Cas protein), the aforementioned fusion protein, the aforementioned polynucleotide, the aforementioned CRISPR-Cas composition, and the aforementioned host cell for use in preparing a kit, wherein the components of the kit are in the same or different containers.

[0397] In one aspect, the present invention also provides a container comprising the aforementioned kit.

[0398] In one embodiment, the container comprises a sterile container;

[0399] In one embodiment, the container comprises a syringe.

[0400] In some embodiments, the kit also includes instructions for using the kit, such as instructions in more than one language. The kit may also include one or more reagents for use in the process of utilizing one or more of the above-mentioned components. The reagents may be provided in any suitable container. For example, the kit may provide one or more reaction or storage buffers. The above-mentioned reagents may be provided in a form (for example, in concentrated or lyophilized form) that requires the addition of one or more other components before use; the buffer may be any buffer, including but not limited to sodium carbonate buffer, sodium bicarbonate buffer, borate buffer, Tris buffer, MOPS buffer, HEPES buffer and combinations thereof. The buffer may have a suitable pH value, for example, it may be alkaline. In some embodiments, the pH of the buffer is between about 7-10.

[0401] treat

[0402] "Treatment" refers to treating or curing the subject's condition, delaying the onset of the symptoms of the condition, and / or delaying the severity of the condition. The term "subject" includes, but is not limited to, various animals, plants, and microorganisms. Animals include mammals, such as bovines, equines, ovines, porcines, canines, felines, lagomorphs, rodents (e.g., mice or rats), non-human primates (e.g., macaques or cynomolgus monkeys), or humans. In certain embodiments, the subject (e.g., a human) suffers from a condition (e.g., a condition caused by a disease-related gene defect). "Plant" is any differentiated multicellular organism capable of photosynthesis, including crop plants at any stage of maturity or development.

[0403] In one aspect, the present invention also provides the use of the aforementioned gene editing protein (Cas protein), the aforementioned fusion protein, the aforementioned polynucleotide, the aforementioned CRISPR-Cas composition, and the aforementioned host cell in the preparation of a drug for treating a condition or disease in a subject in need.

[0404] In one embodiment, the use comprises administering the CRISPR-Cas composition to the subject or to cells ex vivo of the subject;

[0405] In one embodiment, the spacer sequence is complementary to at least 15 nucleotides of the target nucleic acid associated with the condition or disease, and the Cas protein or the fusion protein cleaves the target nucleic acid;

[0406] In one embodiment, the condition or disease comprises cancer or an infectious disease;

[0407] In one embodiment, the cancer comprises one or more of Wilms' tumor, Ewing's sarcoma, neuroendocrine tumor, glioblastoma, neuroblastoma, melanoma, skin cancer, breast cancer, colon cancer, rectal cancer, prostate cancer, liver cancer, kidney cancer, pancreatic cancer, lung cancer, biliary tract cancer, cervical cancer, endometrial cancer, esophageal cancer, gastric cancer, head and neck cancer, medullary thyroid cancer, ovarian cancer, glioma, lymphoma, leukemia, myeloma, acute lymphocytic leukemia, acute myeloid leukemia, chronic lymphocytic leukemia, chronic myeloid leukemia, Hodgkin's lymphoma, non-Hodgkin's lymphoma, or urinary bladder cancer;

[0408] In one embodiment, the condition or disease comprises one or more of cystic fibrosis, atherosclerotic cardiovascular disease (ASCVD), Duchenne muscular dystrophy, Becker muscular dystrophy, alpha-1-antitrypsin deficiency, Pompe disease, myotonic dystrophy, Huntington disease, fragile X syndrome, Friedreich's ataxia, amyotrophic lateral sclerosis, frontotemporal dementia, hereditary chronic kidney disease, hyperlipidemia, Leber congenital amaurosis, sickle cell disease, primary hyperoxaluria (PH1), hypercholesterolemia (FH), hereditary angioedema (HAE), retinal disease, macular degeneration, transthyretin amyloidosis, or beta thalassemia;

[0409] In one embodiment, the infectious agent of the infectious disease comprises one or more of human immunodeficiency virus, herpes simplex virus-1, hepatitis B, or herpes simplex virus-2.

[0410] The main advantages of the present invention include:

[0411] (a) The present invention discovers for the first time a new gene editing protein (Cas protein). The gene editing protein (Cas protein) of the present invention has very good gene editing activity, can effectively edit or cut the target gene, and can effectively treat the symptoms or diseases of subjects in need (for example, one or more of cystic fibrosis, Duchenne muscular dystrophy, Becker muscular dystrophy, alpha-1-antitrypsin deficiency, Pompe disease, myotonic dystrophy, Huntington's disease, fragile X syndrome, Friedreich's ataxia, amyotrophic lateral sclerosis, frontotemporal dementia, hereditary chronic kidney disease, hyperlipidemia, Leber congenital amaurosis, sickle cell disease, hypercholesterolemia, transthyretin amyloidosis, or beta-thalassemia).

[0412] (b) The present invention discovered a new Cas protein that has low homology with the reported Cas enzymes. Compared with the Cas enzymes in the prior art, it exhibits excellent DNA nuclease activity and has broad application prospects.

[0413] The present invention will be further described below in conjunction with specific examples. It should be understood that these examples are intended to illustrate the present invention only and are not intended to limit the scope of the present invention. The experimental methods in the following examples, for which specific conditions are not specified, are generally performed under conventional conditions, such as those described in Sambrook et al., Molecular Cloning: A Laboratory Manual (New York: Cold Spring Harbor Laboratory Press, 1989), or according to the conditions recommended by the manufacturer. Unless otherwise stated, percentages and parts are by weight.

[0414] Unless otherwise specified, the reagents and materials in the examples of the present invention are all commercially available products.

[0415] Example 1 Identification of new Cas proteins

[0416] First, the inventors mined metagenomic data using a computer program and analyzed the metagenomes of uncultured plants. Through de-redundancy and protein cluster analysis, they identified a new Cas protease, named CasW1, with its amino acid sequence shown in SEQ ID No. 1 and its nucleotide coding sequence shown in SEQ ID No. 2. Sequence alignment identified CasW1 as belonging to the Cas12 family.

[0417] By analyzing, predicting, and screening the metagenome, proteins and related elements related to the novel CRISPR-Cas system were obtained. The CRISPR-Cas effector protein of the present invention was compared with existing effector proteins, and it was found that it had low similarity with known Cas proteins.

[0418] Through analysis, it was found that the PAM corresponding to the Cas protein obtained in the present invention is 5'-TTTN, where N represents A / T / G / C; the CRISPR locus of the sample containing CasW1 was annotated by PILER-CR, and the corresponding DNA encoding the direct repeat (DR) sequence was shown in SEQ ID No. 3, and its secondary structure schematic diagram is shown in Figure 10.

[0419] Example 2 In vitro enzyme cleavage experiments verified the cleavage activity of CasW1.

[0420] To verify whether CasW1 is a double-stranded DNA nuclease activity, the inventors verified its cleavage activity.

[0421] 1. Construct the expression vector of CasW1.

[0422] The above-mentioned CasW1-encoding nucleotide sequence fragment was synthesized and cloned into the prokaryotic protein expression vector pET-28a(+) (Biola Bio, #QN1060) using restriction endonuclease digestion and T4 DNA ligase ligation to obtain a ligation product. See Figure 6 for the map.

[0423] The inventors performed PCR on the obtained CasW1 fragment and used EcoRI / NotI double enzyme digestion, and at the same time, performed EcoRI / NotI double enzyme digestion on the prokaryotic protein expression vector pET-28a(+). The CasW1 fragment double enzyme digestion product and the prokaryotic protein expression vector pET-28a(+) double enzyme digestion product were then subjected to agarose gel electrophoresis. The results are shown in Figure 1, showing that the CasW1 nucleotide fragment of the correct size of the digestion product and the pET-28a(+) vector fragment with 11bp in the middle of the EcoRI / NotI digestion site were obtained.

[0424] The inventors then transformed the ligation product into competent E. coli DH5a cells and inoculated the cells onto tadalafil-resistant LB plates. After incubation overnight in an inverted incubator at 37°C, single colonies were selected for Sanger sequencing. Sequencing results revealed a plasmid clone with the correct sequence, which was then used for plasmid extraction to obtain the pET-28a(+)-CasW1 expression vector.

[0425] 2. In vitro purification of CasW1 protein.

[0426] The experimental steps are as follows:

[0427] (1) Transformation: Take out a tube of competent Escherichia coli BL21 (DE3) (Shanghai Weidi Biotechnology Co., Ltd., EC1002) from the -80℃ refrigerator and place it on ice to dissolve for 5 minutes. Then, draw 1ng of pET-28a(+)-CasW1 expression vector plasmid and add it to the competent cells. Use your fingers to flick the bottom of the tube to mix and let it stand on ice for 25 minutes. Heat shock in a 45℃ water bath for 45 seconds, quickly return it to ice and let it stand for 2 minutes. Add 700ul of antibiotic-free LB medium to the centrifuge tube and recover at 37℃, 220rpm for 60 minutes. After recovery is complete, centrifuge at 5000rpm for 1 minute to collect the bacteria, discard 600μl of supernatant, and then gently mix the remaining liquid and competent cells and spread them on the LB plate. Use glass beads to coat the plate.

[0428] (2) Induction: At 9:00 AM the next day, a single colony was picked from the transformed LB plate and cultured in 3 ml of LB liquid medium containing kanamycin (10 mg / ml). The culture was then placed on a shaker and incubated at 37°C, 220 rpm for 8 h. At 5:00 PM, the bacteria in the 3 ml LB medium were transferred to 300 ml of 2x YT medium containing kanamycin. 150 μl of IPTG (final concentration 0.5 mM) was added to the bacterial suspension and induced overnight at 16°C for 13-14 h.

[0429] (3) Harvesting the bacteria: Centrifuge the induction solution at 4500 rpm and 4°C for 10 min, and discard the supernatant. Resuspend the bacteria in a 50 ml centrifuge tube with 15 ml of imidazole (10 mM concentration) (imidazole is added for competitive elution of CasW1 protein), and then add 150 μl of PMSF protease inhibitor (to inhibit protein degradation and improve yield).

[0430] (4) Ultrasound: Place a 50 ml centrifuge tube upright in a beaker filled with ice water. Adjust the position so that the ultrasonic probe is below the bacterial liquid level. Ultrasound mode: 3 s on, 12 s off, 200 W, 60 cycles. After the ultrasonication, add 150 μl of PMSF protease inhibitor and centrifuge at 11,000 rpm and 4°C for 25 min.

[0431] (5) Bead pretreatment: Pipette 300 μl of Ni-NTA Agarose beads (QIAGEN, #30230) into a 15 ml centrifuge tube, add 10 ml of PBS, rotate at room temperature for 5 min, centrifuge at 1000 g for 2 min, and then at 4°C. Remove the supernatant with a pipette and repeat the wash with PBS. Then add 10 ml of imidazole (10 mM concentration), rotate at room temperature for 5 min, centrifuge at 1000 g for 2 min, and then at 4°C. Carefully remove the supernatant with a pipette and place the 15 ml centrifuge tube containing the washed beads on ice for later use.

[0432] (6) The supernatant of the bacterial solution obtained after centrifugation in step (4) was aspirated into the centrifuge tube containing Ni-NTA Agarose beads obtained in step (5) and incubated with rotation at 4°C for 1 h.

[0433] (7) Wash: Ni-NTA Agarose beads were eluted twice with 10 ml imidazole (40 mM concentration). After each addition of imidazole, the beads were rotated at 4°C for 5 min, and then centrifuged at 1000 × g for 2 min at 4°C. Ni-NTA Agarose beads were resuspended with 500 μl imidazole (250 mM concentration) and then transferred to a pre-cooled affinity chromatography column (MedChemExpress, #HY-K0221). The beads were equilibrated for 5 min and the protein fraction eluted with 250 mM imidazole was collected in a 1.5 ml centrifuge tube. The above elution steps were repeated three times.

[0434] (8) After measuring the protein concentration of each tube using NanoDrop OD280, the protein solution was collected and replaced with PBS buffer through a 30 kD ultrafiltration tube. Glycerol was added to a final concentration of 10%, and the aliquots were quickly frozen in liquid nitrogen and stored in a -80°C refrigerator. SDS-PAGE polyacrylamide gel electrophoresis was used to identify the protein size and purity. As shown in Figure 2, the size of the CasW1 protein was approximately 130 kD, indicating that a well-purified CasW1 protein had been obtained.

[0435] 3. In vitro cleavage verification

[0436] 3.1 Preparation of in vitro cleaved dsDNA template.

[0437] Using the HepG2 cell (ATCC, Catalog No. HB-8065) ​​genome as a template, forward and reverse primers were prepared based on the hHPRT1 gene (Genebank, NG_012329.2) dsDNA template. The upstream and downstream primers are as follows:

[0438] hHPRT1-dsDNA-F: gtagtgtcaactcattgctg (SEQ ID NO.5);

[0439] hHPRT1-dsDNA-R: gtcaagggcatatcctacaa (SEQ ID NO. 6).

[0440] Taq enzyme was used for PCR amplification, and the reaction system was as follows:

[0441] 1 μl of genomic DNA (as template) (total amount 100 ng), 10 μl of 2×Taq PCR mix, 0.5 μl of upstream and downstream primers respectively, and ddH2O were added to make up the total volume to 20 μl.

[0442] The PCR reaction program was as follows: 95°C for 5 min; 94°C for 30 s, 55°C for 30 s, 72°C for 20 s, 35 cycles; 72°C for 10 min; and insulation at 12°C.

[0443] The PCR reaction solution was then subjected to agarose gel electrophoresis, and the electrophoresis results are shown in Figure 3. The gel was then recovered using an agarose gel DNA recovery kit (TIANGEN, DP219-02), and finally eluted with enzyme-free water to obtain the in vitro cleaved dsDNA template.

[0444] 3.2 In vitro enzymatic digestion reaction.

[0445] To detect the cleavage activity of CasW1, the inventors designed two sets of comparative experiments to compare their cleavage activities. The first set compared the cleavage activities of CasW1 and LbCpf1, and the second set compared the cleavage activities of CasW1 with HED Cas 12i.16 and S7R-Cas12i.3.

[0446] Among them, the amino acid sequence of the LbCpf1 protein is shown in SEQ ID NO.12, and the nucleotide coding sequence is shown in SEQ ID NO.11; the amino acid sequence of the HED Cas12i.16 protein is shown in SEQ ID NO.10, and the nucleotide sequence is shown in SEQ ID NO.9; the amino acid sequence of S7R-Cas12i.3 is shown in SEQ ID NO.8, and the nucleotide sequence is shown in SEQ ID NO.7.

[0447] The method of step 1 in Example 2 was used to construct LbCpf1, HED Cas12i.16, and S7R-Cas 12i.3 expression vectors, respectively. The maps of the recombinant expression vectors are shown in Figures 7, 8, and 9.

[0448] 3.2.1 Comparison of cleavage activity of CasW1 and LbCpf1

[0449] The specific steps are as follows:

[0450] (1) Prepare CasW1-crRNA and LbCpf1-crRNA respectively.

[0451] A targeting sequence (spacer) was designed based on the hHPRT1 gene and named hHPRT1-spacer: GGTTAAAGATGGTTAAATGAT (SEQ ID NO. 4).

[0452] Based on the DR sequences of CasW1 and LbCpf1, the crRNA sequences of the above Cas proteins were designed and named CasW1-hHPRT1-crRNA and LbCpf1-hHPRT1-crRNA, respectively, as follows:

[0453] CasW1-hHPRT1-crRNA:

[0454] GTCTAAATGACCTATAAATTTCTACTATGTGTAGATGGTTAAAGATGGTTAAATGAT (SEQ ID NO. 13), wherein the underlined sequence is the DR sequence of CasW1;

[0455] LbCpf1-hHPRT1-crRNA:

[0456] TAATTTCTACTAAGTGTAGATGGTTAAAGATGGTTAAATGAT (SEQ ID NO. 14), wherein the underlined sequence is the DR sequence of LbCpf1;

[0457] CasW1-hHPRT1-crRNA and LbCpf1-hHPRT1-crRNA sequence fragments were chemically synthesized (by Nanjing GenScript Biotechnology Co., Ltd.). A mixed solution of CasW1 and CasW1-hHPRT1-crRNA was then prepared, and the components of the mixed solution were as follows:

[0458] 20 μl of enzyme-free H2O, 3 μl of NEBuffer r2.1 (10×, NEB, #B6002S), 3 μl of crRNA (CasW1-hHPRT1-crRNA or LbCpf1-hHPRT1-crRNA) (concentration: 30 nM), 1 μl of Cas protein (CasW1 or LbCpf1) (concentration: 30 nM), and the total reaction volume was 27 μl.

[0459] A mixed solution of LbCpf1 and LbCpf1-hHPRT1-crRNA was prepared in the same manner.

[0460] Then, the mixed solution of CasW1 and CasW1-hHPRT1-crRNA, and the mixed solution of LbCpf1 and LbCpf1-hHPRT1-crRNA were placed in a PCR instrument respectively and reacted at 25°C for 10 minutes.

[0461] (2) Add 3uL of 60nM dsDNA solution (final concentration is 6nM) to the mixed solution of CasW1 and CasW1-hHPRT1-crRNA and the mixed solution of LbCpf1 and LbCpf1-hHPRT1-crRNA after the reaction, respectively. The total reaction system is 30μl, mix thoroughly, centrifuge briefly, and incubate in a PCR instrument at 37°C for 10 minutes.

[0462] (3) Add 1 μL of Proteinase K to the reaction system in the previous step, mix thoroughly, centrifuge briefly, and incubate at room temperature for 10 minutes to digest the protein components in the reaction system;

[0463] (4) Use magnetic beads to purify the DNA fragments after enzyme digestion reaction.

[0464] Take out the DNA sorting magnetic bead solution (Novozyme, product number N411-02) from the 4°C refrigerator 20 minutes in advance and equilibrate to room temperature. Mix the magnetic beads by turning them upside down, draw 3 times the volume (about 150 μl) of the magnetic bead solution and add it to the dsDNA cleavage product obtained in step (3), and use a pipette to gently blow 10 times to mix, incubate at room temperature for 10 minutes to allow the dsDNA cleavage product to bind to the magnetic beads. Place the PCR tube containing the dsDNA cleavage product sample solution on the magnetic rack, and carefully remove the supernatant after the solution is clarified. Keep the aforementioned PCR tube on the magnetic rack at all times, add 200 μl of freshly prepared 80% ethanol to rinse the magnetic beads, incubate at room temperature for 30 seconds, and carefully remove the supernatant. Repeat the rinse once. Open the lid and dry the magnetic beads at room temperature for 5 minutes, remove the PCR tube from the magnetic rack, add 15 μl of enzyme-free water, vortex or use a pipette to mix thoroughly, and let it stand at room temperature for 2 minutes. Then place the PCR tube on a magnetic stand and let it stand for 5 minutes. After the solution is clarified, carefully pipette the supernatant into a new nuclease-free PCR tube.

[0465] (5) The dsDNA cleavage products were then analyzed using a portable bioanalyzer (Houze Biotechnology, Qsep1) and the enzyme cleavage effect was detected using the S1 high-resolution cartridge (Houze Biotechnology, C105102) detection protocol. The analysis results are shown in Figure 4. The Smear analysis option provided by Qsep1 showed that the cleavage activity of CasW1 was 99.5%, and the cleavage activity of LbCpf1 was 95%. The cleavage activity of CasW1 was higher than that of LbCpf1.

[0466] Comparison of cleavage activity of CasW1, HED Cas12i.16, and S7R-Cas12i3

[0467] The specific steps are as follows:

[0468] (1) Prepare crRNAs of CasW1, HED Cas12i.16, and S7R-Cas12i3, respectively.

[0469] The hHPRT1-spacer sequence fragment was synthesized. Based on the DR sequences of CasW1, HED Cas12i.16, and S7R-Cas12i3, the crRNA sequences of the above Cas proteins were designed and named CasW1-hHPRT1-crRNA, HED Cas12i.16-hHPRT1-crRNA, and S7R-Cas12i3-hHPRT1-crRNA, respectively. The specific sequences are as follows:

[0470] CasW1-hHPRT1-crRNA:

[0471] GTCTAAATGACCTATAAATTTCTACTATGTGTAGATGGTTAAAGATGGTTAAATGAT (SEQ ID NO. 13), wherein the underlined sequence is the DR sequence of CasW1;

[0472] HED Cas12i.16-hHPRT1-crRNA:

[0473] CTAGCAATGACTCAGAAATGTGTCCCCAGTTGACACGGTTAAAGATGGTTAAATGAT (SEQ ID NO. 15), wherein the underlined sequence is the DR sequence of HED Cas12i.16;

[0474] S7R-Cas12i3-hHPRT1-crRNA:

[0475] AGAGAATGTGTGCATAGTCACACGGTTAAAGATGGTTAAATGAT (SEQ ID NO. 16), wherein the underlined sequence is the DR sequence of S7R-Cas12i3;

[0476] CasW1-hHPRT1-crRNA, HED Cas12i.16-hHPRT1-crRNA and S7R-Cas12i3-hHPRT1-crRNA sequence fragments were chemically synthesized (by Nanjing GenScript Biotechnology Co., Ltd.).

[0477] (2) Referring to the cleavage activity comparison experiment in step 3.2.1, in vitro enzyme cleavage experiments were performed on CasW1, HED Cas12i.16, and S7R-Cas12i3, respectively. Finally, the DNA fragments after the enzyme cleavage reaction were purified using magnetic beads.

[0478] (3) The dsDNA cleavage products were then analyzed using a portable bioanalyzer (Houze Bio, Qsep1), and the enzyme cleavage effect was detected with reference to the S1 high-resolution cartridge (Houze Bio, C105102) detection protocol. The analysis results are shown in Figure 5. The Smear analysis option provided by Qsep1 showed that the cleavage activity of CasW1 was 100%, the cleavage activity of HED Cas12i.16 was 14%, and the cleavage activity of S7R-Cas12i3 was 58%. The cleavage activity of CasW1 was much higher than that of HED Cas12i.16 and S7R-Cas12i3.

[0479] Sequence information:

[0480] All documents mentioned in this application are incorporated herein by reference, just as if each document were incorporated herein by reference individually. It should also be understood that after reading the above teachings of the present invention, those skilled in the art may make various changes or modifications to the present invention, and that such equivalents also fall within the scope of the claims appended hereto.

Claims

1. A gene editing protein, It is characterized in that The protein is selected from the group consisting of: (a) a polypeptide having the amino acid sequence shown in SEQ ID NO: 1; (b) a polypeptide having ≥80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 99.5% homology (or identity) with the amino acid sequence of SEQ ID NO: 1, and the polypeptide has the biological function of SEQ ID NO: 1; (c) A derivative polypeptide formed by replacing, deleting or adding one or more (preferably 1-20, more preferably 1-10, and more preferably 1-5) amino acid residues of any one of the amino acid sequences shown in SEQ ID NO: 1, and retaining the biological function of SEQ ID NO:

1.

2. A fusion protein, It is characterized in that Comprising the gene editing protein of claim 1; and one or more functional domains.

3. An isolated polynucleotide, It is characterized in that The polynucleotide encodes the gene editing protein according to claim 1 or the fusion protein according to claim 2.

4. An isolated nucleic acid molecule, It is characterized in that It comprises a sequence selected from the following, or consists of a sequence selected from the following: (i) the sequence shown in SEQ ID NO: 3; (ii) a sequence having one or more base substitutions, deletions or additions (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 base substitutions, deletions or additions) compared to the sequence shown in SEQ ID NO: 3; (iii) a sequence having at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95% sequence identity to the sequence shown in SEQ ID NO: 3; (iv) a sequence that hybridizes to the sequence described in any one of (i) to (iii) under stringent conditions; or (v) a complementary sequence of the sequence described in any one of (i) to (iii); Furthermore, the sequence described in any one of (ii) to (v) substantially retains the biological function of the sequence from which it is derived; For example, the isolated nucleic acid molecule is RNA; For example, the isolated nucleic acid molecule comprises a direct repeat sequence in a CRISPR / Cas system.

5. A guide RNA (gRNA), It is characterized in that The guide RNA includes a direct repeat (DR) sequence capable of binding to the gene editing protein of claim 1 and a spacer sequence capable of targeting a target sequence.

6. A composite, It is characterized in that Include: (i) a protein component selected from the group consisting of the gene editing protein of claim 1, the fusion protein of claim 2, or a combination thereof; and (ii) a nucleic acid component selected from the group consisting of the guide RNA of claim 5, a nucleic acid encoding the guide RNA of claim 5, a precursor RNA of the guide RNA of claim 5, a precursor RNA nucleic acid encoding the guide RNA of claim 5, or a combination thereof; Wherein, the protein component and the nucleic acid component are combined with each other to form a complex.

7. A carrier, It is characterized in that Comprising the polynucleotide according to claim 3 or the nucleic acid molecule according to claim 4.

8. A CRISPR-Cas composition, It is characterized in that Include: (i) a first component selected from the group consisting of the gene editing protein of claim 1, the fusion protein of claim 2, a nucleotide sequence encoding the gene editing protein of claim 1 or the fusion protein of claim 2, and any combination thereof; and (ii) a second component, which comprises one or more guide RNAs according to claim 5, or a nucleotide sequence encoding the one or more guide RNAs according to claim 5; The guide RNA is capable of forming a complex with the protein, protein variant or fusion protein described in (i).

9. A CRISPR-Cas system, It is characterized in that Comprising one or more vectors, the one or more vectors comprising: (i) a first nucleic acid, which is a nucleotide sequence encoding the gene editing protein of claim 1 or the fusion protein of claim 2; optionally, the first nucleic acid is operably linked to a first regulatory element; as well as (ii) a second nucleic acid encoding a nucleotide sequence comprising the guide RNA of claim 5; optionally, the second nucleic acid is operably linked to a second regulatory element; in: The first nucleic acid and the second nucleic acid are present on the same or different vectors; The guide RNA is capable of forming a complex with the protein or fusion protein described in (i).

10. A kit, It is characterized in that Comprising one or more components selected from the following: the gene editing protein of claim 1, the fusion protein of claim 2, the polynucleotide of claim 3, the complex of claim 6, the vector of claim 7, the CRISPR-Cas composition of claim 8, or the system of claim 9.

11. A delivery composition, It is characterized in that Comprising a delivery vector and one or more selected from the following: the gene editing protein of claim 1, the fusion protein of claim 2, the polynucleotide of claim 3, the complex of claim 6, the vector of claim 7, the CRISPR-Cas composition of claim 8, or the system of claim 9.

12. A host cell, It is characterized in that Comprising the gene editing protein of claim 1, the fusion protein of claim 2, the polynucleotide of claim 3, the nucleic acid molecule of claim 4, the complex of claim 6, the vector of claim 7, the CRISPR-Cas composition of claim 8, or the system of claim 9, or the delivery composition of claim 11.

13. An enzyme preparation, It is characterized in that The enzyme preparation comprises the gene editing protein of claim 1, the fusion protein of claim 2, the complex of claim 6, the CRISPR-Cas composition of claim 8, the system of claim 9, or the delivery composition of claim 11.

14. A medicine box, It is characterized in that include: A first container, and the complex according to claim 6, the composition according to claim 8, or the system according to claim 9, or a drug containing the complex according to claim 6, the composition according to claim 8, or the system according to claim 9 located in the first container.

15. A medicine box, It is characterized in that include: (a1) a first container, and the gene editing protein according to claim 1, or the fusion protein according to claim 2, or the gene encoding it or its expression vector, or a drug containing the gene editing protein according to claim 1, or the fusion protein according to claim 2, or the gene encoding it or its expression vector, located in the first container; (b1) an optional second container, and the guide according to claim 5 located in the second container RNA or its expression vector, or a drug containing the guide RNA or its expression vector according to claim 5.

16. A method for targeting and editing a target gene or cleaving a target gene, It is characterized in that include: The gene editing protein of claim 1, or the fusion protein of claim 2, or the complex of claim 6, or the composition of claim 8, or the system of claim 9, or the delivery composition of claim 11, or the enzyme preparation of claim 13, or the drug kit of claim 14 or 15 is contacted with the target gene, or delivered to a cell containing the target gene, and the target sequence is present in the target gene.

17. A method of inducing a change in cell state, It is characterized in that The method comprises contacting the gene editing protein of claim 1, or the fusion protein of claim 2, or the complex of claim 6, or the composition of claim 8, or the system of claim 9, or the delivery composition of claim 11, or the enzyme preparation of claim 13, or the drug kit of claim 14 or 15 with a target gene in a cell.

18. A method of altering the expression of a gene product, It is characterized in that include: The gene editing protein of claim 1, or the fusion protein of claim 2, or the complex of claim 6, or the composition of claim 8, or the system of claim 9, or the delivery composition of claim 11, or the enzyme preparation of claim 13, or the kit of claim 14 or 15 is contacted with a nucleic acid molecule encoding the gene product, or delivered to a cell containing the nucleic acid molecule, wherein the target sequence is present in the nucleic acid molecule.

19. An in vitro, ex vivo or in vivo cell or cell line or a progeny thereof, It is characterized in that The cell or cell line or their progeny comprises: the gene editing protein of claim 1, or the fusion protein of claim 2, or the polynucleotide of claim 3, or the complex of claim 6, or the vector of claim 7, or the composition of claim 8, or the system of claim 9, or the delivery composition of claim 11.

20. Use of the gene editing protein of claim 1, or the fusion protein of claim 2, or the polynucleotide of claim 3, or the nucleic acid molecule of claim 4, or the complex of claim 6, or the vector of claim 7, or the composition of claim 8, or the system of claim 9, or the kit of claim 10, or the delivery composition of claim 11, or the enzyme preparation of claim 13, or the kit of claim 14 or 15, It is characterized in that For use in the preparation of a medicament or formulation for nucleic acid editing (e.g., gene or genome editing).

21. Use of the gene editing protein of claim 1, or the fusion protein of claim 2, or the polynucleotide of claim 3, or the complex of claim 6, or the vector of claim 7, or the composition of claim 8, or the system of claim 9, or the kit of claim 10, or the delivery composition of claim 11, or the enzyme preparation of claim 13, or the kit of claim 14 or 15, It is characterized in that For use in the preparation of a drug or preparation, the drug or preparation is used for one or more selected from the following groups: (i) ex vivo gene or genome editing; (ii) Detection of single-stranded DNA in vitro; (iii) editing a target sequence in a target locus to modify an organism or non-human organism; (iv) treating a disorder caused by a defect in the target sequence in the target locus; (v) treating a condition or disease in a subject in need thereof.

22. A method for detecting the presence of a target nucleic acid molecule in a sample, It is characterized in that The method comprises contacting the sample with the gene editing protein of claim 1, or the fusion protein of claim 2, or the complex of claim 6, or the composition of claim 8, or the system of claim 9, or the kit of claim 10, or the delivery composition of claim 11, or the enzyme preparation of claim 13, and a non-target sequence, and detecting a detectable signal generated by the cleavage of the non-target sequence, thereby detecting the target nucleic acid molecule, wherein the non-target sequence does not hybridize with the guide RNA.

Citation Information

Patent Citations

  • Cas12 protein, gene editing system containing Cas12 protein and application thereof

    CN113373130A

  • Gene editing protein, corresponding gene editing system and application thereof

    CN116622678A

  • Compounds for increasing genome editing efficiency

    EP3388517A1

  • Novel Class 2 Type II and Type V CRISPR-Cas RNA-Guided Endonucleases

    US20220398426A1

  • Novel cas enzyme and system and use thereof

    WO2022100527A1